Romania

Show information for:

Information and guides

BackSavedSign in

Support / Info

Clinical trials for lung cancer in Romania

Which studies are listed as recruiting, where the centres are, and how to contact the team. Record source: ClinicalTrials.gov.

← All cancer types

How to read this list

Each card is a study listed as recruiting with a recruiting centre in Romania. Open the sections in the card to see the participant overview, study groups, calendar and all published local centres and contacts. The study team confirms eligibility and availability; the original registry record remains available for the complete protocol information.

Trials recruiting now

38 of 39 titles have been rewritten in plain language by our editorial team. The rest still show the registry's protocol wording.

Trials testing a treatment · 38 studies

Something new is being tried here: a medicine, a regimen or a procedure. If you join, you receive either the treatment under study or the standard one, and the team follows you closely.

NCT04928846Phase 3Listed as recruiting

Previously treated non-squamous lung cancer: telisotuzumab vedotin compared with docetaxel

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Minimum age: 18 years

Centres in: Brașov · Cluj-Napoca · Craiova · and 5 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT04928846. This contact may be in another country; ask which language you can use.

ABBVIE CALL CENTER

844-663-3742 (dialling format unconfirmed)

abbvieclinicaltrials@abbvie.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

Cluj-Napoca

Craiova

Iași

Oradea

Otopeni

Suceava

Timișoara

Who can take part

Previously treated non-squamous lung cancer: telisotuzumab vedotin compared with docetaxel

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin or docetaxel at an 1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin or IV infusion of docetaxel. Approximately 768 adult participants with c-Met overexpressing NSCLC will be enrolled in the study in approximately 330 sites worldwide. Participants will receive IV telisotuzumab vedotin every 2 weeks or docetaxel every 3 weeks until meeting study drug discontinuation criteria. At the conclusion of the study, participants who continue to demonstrate clinical benefit may be eligible to receive study treatment via an extension of the study, a rollover study, or through another mechanism. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Projected life expectancy of at least 12 weeks. * Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay. * Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor material from the primary tumor site and/or metastatic sites are allowed. * If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except China). * A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic. * A known epidermal growth factor receptor (EGFR) activating mutation status. \-- Participants with EGFR activating mutations are not eligible * Actionable alterations in genes other than EGFR are eligible. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * An Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1. * Have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting. * Have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC * Participants WITHOUT an actionable gene alteration: must have progressed on (or be considered ineligible for) platinum-based chemotherapy and immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). * Participants WITH an actionable gene alteration for which immune checkpoint inhibitor therapy is not standard of care (e.g., anaplastic lymphoma kinase \[ALK\] translocation): must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alterations and platinum-based chemotherapy. * Participants with gene alterations for which immune checkpoint inhibitor is standard of care must have also progressed on (or be considered ineligible for) immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). * Must be considered appropriate for docetaxel therapy based on the assessment of the treating physician. * Participants with metastases to the central nervous system (CNS) are eligible only after adequate treatment (such as surgery, radiotherapy, or drug therapy) is provided and: * They are asymptomatic and off or on a stable or reducing dose of systemic steroids (on no more than 10 mg per day \[QD\] prednisone or equivalent) and/or anticonvulsants for at least 2 weeks prior to randomization. Exclusion Criteria: * Evidence of new, untreated CNS metastases or progressing CNS metastases after treatment. * Evidence of leptomeningeal disease. * Participants with adenosquamous or neuroendocrine histology, nor sarcomatoid features. * Epidermal growth factor receptor (EGFR) activating mutations. * Participants who have received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.. * Participants who have received prior docetaxel therapy. * A history of other malignancies except: * Malignancy treated with curative intent and with no known active disease present for \>=2 years before the first dose of study drug and felt to be at low risk for recurrence by investigator. Additionally, participants must not be receiving any ongoing anti-cancer therapy, including maintenance therapy, prior to randomization.. * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. * Adequately treated carcinoma in situ without current evidence of disease. * A history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, evidence of active pneumonitis on screening chest computed tomography (CT) scan or prior pneumonectomy. A history of prior radiation pneumonitis in the radiation field (fibrosis) is not permitted. * Unresolved nor adverse event (AE) \>= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study. * Major surgery within 21 days prior to randomization. * Clinically significant condition(s) as listed in the protocol.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Telisotuzumab Vedotin

  • Group 2 · Active treatment comparison

    Docetaxel

Start of the whole study
25 March 2022
Completion of the whole study
February 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Updated in the registry: 29 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06767514Phase 3Listed as recruiting

First-line metastatic lung cancer with high PD-L1: ivonescimab

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Minimum age: 18 years

Centres in: Baia Mare · București · Cluj-Napoca · and 5 more cities

See all centres (11)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06767514. This contact may be in another country; ask which language you can use.

Summit Clinical Trial Information

1-833-256-0522 (dialling format unconfirmed)

medicalinformation@smmttx.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Baia Mare

București

Cluj-Napoca

Craiova

Iași

Ovidiu

Suceagu

Timișoara

Who can take part

First-line metastatic lung cancer with high PD-L1: ivonescimab

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Age ≥ 18 years old at the time of enrollment * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1 * Expected life expectancy ≥ 3 months * Metastatic (Stage IV) NSCLC * Histologically or cytologically confirmed squamous or non-squamous NSCLC * Tumor demonstrates high PD-L1 expression ( TPS\>50%) based on a 22C3 immunohistochemistry ( IHC) clinical assay approved / cleared by local health authorities. * At least one measurable noncerebral lesion according to RECIST 1.1 * No prior systemic treatment for metastatic NSCLC. Exclusion Criteria: * Histologic or cytopathologic evidence of the presence of small cell lung carcinoma for which first-line approved therapies are indicated. For patients with non-squamous histology, actionable driver mutation testing results are required before randomization. * Has received any prior therapy for NSCLC in the metastatic setting. * Concurrent enrollment in another clinical study, unless patient is enrolled in a non-interventional clinical study or is completing survival follow -up. * Known actionable genomic alterations for which first-line approved therapies are indicated * Symptomatic CNS metastases, CNS metastasis ≥ 1.5 cm, CNS radiation within 7 days prior to randomization, potential need for CNS radiation within the first cycle, or leptomeningeal disease * Other prior malignancy (including previously treated NSCLC) unless the patient has undergone curative therapy with no evidence of recurrence of the disease for 3 years prior to randomization * Active autoimmune or lung disease requiring systemic therapy * Has pre-existing peripheral neuropathy that is ≥ Grade 2 by CTCAE version 5 * Severe infection within 4 weeks prior to randomization * Major surgical procedures or serious trauma within 4 weeks prior to randomization * History of noninfectious pneumonia requiring systemic corticosteroids, or current interstitial lung disease

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Ivonescimab Injection

  • Group 2 · Active treatment comparison

    Pembrolizumab Injection

Start of the whole study
27 February 2025
Completion of the whole study
June 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Updated in the registry: 18 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06422143Phase 3Listed as recruiting

Metastatic squamous lung cancer: pembrolizumab with or without sacituzumab tirumotecan maintenance

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).

Minimum age: 18 years

Centres in: Brașov · București · Cluj-Napoca · and 4 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06422143. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • SC ONCO CARD SRL

    Contact for this study

    Study Coordinator

    +40 268 960

    Source: study registry

București

  • Centrul Medical Medicover Victoria

    Contact for this study

    Study Coordinator

    +40 21 9896

    Source: study registry

  • Lotus-Med

    Contact for this study

    Study Coordinator

    +40 21 9989

    Source: study registry

Cluj-Napoca

  • Cardiomed SRL Cluj-Napoca

    Contact for this study

    Study Coordinator

    +40 264 406 600

    Source: study registry

Craiova

  • Centrul de Oncologie Sfantul Nectarie-Medical

    Contact for this study

    Study Coordinator

    +40 731 604 432

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala

    Contact for this study

    Study Coordinator

    +40 21 9368

    Source: study registry

Sibiu

  • Clinica Polisano

    Contact for this study

    Study Coordinator

    +40 21 9383

    Source: study registry

Timișoara

  • Cabinet Medical Oncomed

    Contact for this study

    Study Coordinator

    +40 356 460 995

    Source: study registry

Who can take part

Metastatic squamous lung cancer: pembrolizumab with or without sacituzumab tirumotecan maintenance

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (NSCLC) \[Stage IV: M1a, M1b, M1c, American Joint Committee on Cancer Staging Manual, version 8\] * Measurable disease per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 as assessed by the local site investigator/radiology * Has life expectancy ≥3 months * Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 assessed within 7 days prior to allocation * Archival tumor tissue sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg)-positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before allocation * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening * Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline (participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible) * Has adequate organ function * For Maintenance only (prior to randomization): is without disease progression of their NSCLC, as determined by BICR using RECIST 1.1 after completion of study-specified Induction with an evaluable scan at Week 12 or most recent scan before randomization * For Maintenance only (prior to randomization): has ECOG PS of 0 or 1 as assessed at the Prerandomization Visit * For Maintenance only (prior to randomization): all AEs (with the exception of alopecia, Grade ≤2 fatigue, Grade ≤2 peripheral neuropathy, and Grade ≤2 endocrine-related AEs requiring treatment or hormone replacement) have recovered * For Maintenance only (prior to randomization): has not experienced a pneumonitis/interstitial lung disease (ILD) event during the study-specified induction Exclusion Criteria: * Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * History of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>480 ms, and other serious cardiovascular and cerebrovascular diseases within 6 months before study intervention * HIV-infected participants who have been newly diagnosed or with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC. Note: Prior treatment with chemotherapy and/or radiation as a part of neoadjuvant or adjuvant therapy or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti programmed cell death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T lymphocyte-associated protein 4, OX-40, CD137). Note: Prior treatment with an anti-PD-1 or anti-PD-L1 agent for nonmetastatic NSCLC is allowed as long as therapy was completed at least 12 months before diagnosis of metastatic NSCLC * Received prior treatment with a trophoblast cell-surface antigen 2 (TROP2)-targeted antidrug conjugate (ADC) * Received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention * Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention * Participants who have not adequately recovered from major surgery or have ongoing surgical complications * Received prior treatment with a topoisomerase I inhibitor-containing ADC * Is currently receiving a strong inducer/inhibitor of CYP3A4 that cannot be discontinued for the duration of the study (the required washout period before starting sac-TMT is 2 weeks) * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. * Has known central nervous system (CNS) metastases/carcinomatous meningitis * Severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients or to another biologic therapy * Active autoimmune disease that has required systemic treatment in the past 2 years (replacement therapy \[eg, thyroxine, insulin, or physiologic corticosteroid\] is allowed) * Has a history of (noninfectious)pneumonitis/ILD that required steroids, has current pneumonitis/ILD, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at Screening * Active infection requiring systemic therapy * History of allogeneic tissue/solid organ transplant

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pembrolizumab · sac-TMT · Carboplatin · Paclitaxel · Nab-paclitaxel

  • Group 2 · Active treatment comparison

    Pembrolizumab · Carboplatin · Paclitaxel · Nab-paclitaxel

Start of the whole study
10 June 2024
Completion of the whole study
15 August 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

Updated in the registry: 17 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06712355Phase 3Listed as recruiting

Untreated small cell lung cancer: BNT327 alongside chemotherapy

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Minimum age: 18 years

Centres in: Baia Mare · București · Cluj-Napoca · and 4 more cities

See all centres (9)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06712355. This contact may be in another country; ask which language you can use.

BioNTech clinical trials patient information

+4961319084

patients@biontech.de

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Baia Mare

București

Cluj-Napoca

Craiova

Iași

Onești

Timișoara

Who can take part

Untreated small cell lung cancer: BNT327 alongside chemotherapy

This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study Group \[VALG\]'s two stage classification scheme). For AJCC tumor node metastasis staging system: AJCC 8th edition stage IV (T any, N any, M1a/b/c), or T3\~4 for multiple lung nodules or tumor/nodule volume that cannot be encompassed in a tolerable radiotherapy plan. * Have not had prior systemic therapy for ES-SCLC. However, participants with prior chemoradiotherapy for limited-stage-SCLC must have been treated with curative intent and had a treatment-free interval of at least 6 months after the last chemotherapy, radiotherapy, or chemoradiotherapy before diagnosis of ES-SCLC to be eligible. * Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion). * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate hematologic and organ function as defined in the protocol. Exclusion Criteria: * Have histologically or cytologically confirmed SCLC with combined histologies. * Have received any of the following therapies or drugs within the noted time intervals prior to study treatment: * Within 2 weeks: small molecule agents with half-life of \<7 days; radiation outside the thoracic cavity including whole brain radiation. Of note, other local radiation for brain lesions (not whole brain) is allowed; local radiation for bone lesions is allowed. Palliative bone radiation or brain stereotactic radiosurgery would not require a washout period, but participants should recover from radiotherapy-related toxicity. * Within 4 weeks: radiation involving the thoracic cavity; small molecule targeted agents with half-life of ≥7 days; monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies. * Have received prior treatment with anti-vascular endothelial growth factor (VEGF) monoclonal antibody, or programmed death (ligand)-1 (PD\[L\]-1)/VEGF bispecific antibody. * Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (≤7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) are allowed. * Have the following central nervous system metastases: * Participants with untreated brain metastases that are symptomatic or large (e.g., greater than 2 cm). * Participants with treated central nervous system (CNS) metastases who are not neurologically stable or on steroids (at a dosage greater than 10 mg/Day of prednisone or an equivalent dose of other corticosteroid) within 7 days before initiating study treatment of this study. * Participants with known leptomeningeal metastases. * Have uncontrolled hypertension or poorly controlled diabetes prior to study treatment. * Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess for which an interval of 6 months must pass before study entry. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation. * Have a significant risk of hemorrhage (per investigator clinical judgment) as defined in the protocol. * Have superior vena cava syndrome or symptoms of spinal cord compression that requires urgent medical intervention. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Active treatment comparison

    Atezolizumab · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Group 2 · Studied intervention

    Pumitamig · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Group 3 · Studied intervention

    Pumitamig · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Group 4 · Active treatment comparison

    Atezolizumab · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated)

  • Group 5 · Studied intervention

    Pumitamig · Etoposide · Carboplatin (or cisplatin if carboplatin is not tolerated)

Start of the whole study
3 February 2025
Completion of the whole study
July 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Updated in the registry: 14 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06801834Phase 3Listed as recruiting

Previously treated extensive-stage small cell lung cancer: sacituzumab govitecan compared with standard care

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 4 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06801834. This contact may be in another country; ask which language you can use.

Gilead Clinical Study Information Cente

GileadClinicalTrials@gilead.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Iași

Ovidiu

Ploiești

Timișoara

Who can take part

Previously treated extensive-stage small cell lung cancer: sacituzumab govitecan compared with standard care

The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this study are to compare the effect of SG to SOC on overall survival (OS).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Key Inclusion Criteria: * Histologically confirmed diagnosis of SCLC. * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1. * Measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by investigator per RECIST v1.1 criteria. * Documentation of radiological disease progression after 1 prior line of platinum-containing chemotherapy (defined as at least 2 cycles of treatment) with or without therapy directed against programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1; PD-1 and PD-L1 are hereafter referred to as PD-(L)1) for ES-SCLC. * Individuals treated with a platinum-based therapy for prior limited stage small cell lung cancer will be counted as 1 prior line of platinum-containing chemotherapy if the disease has progressed within 30 to 180 days from last dose of platinum treatment. * If the investigator believes a participant may benefit from platinum rechallenge it can be considered per investigator discretion and local SOC; however, participants with platinum rechallenge may not participate in the study. * If the investigator believes a participant may benefit from tarlatamab treatment, it can be considered per investigator discretion and local SOC and such participants may participate in the study following tarlatamab treatment. Note: at least 85% of participants included in the study must be pretreated with anti-PD-\[L\]1 therapy. Refer to protocol for country-specific requirements for participants in China. Key Exclusion Criteria: * Chemotherapy-free interval (CTFI) time from the last dose of first-line platinum-containing chemotherapy to the occurrence of progressive disease) \< 30 days (independent of the immunotherapy maintenance). * Received any prior treatment with irinotecan, topotecan, SG, SN-38, exatecan derivatives, and similar agents targeting topoisomerase I. Received lurbinectedin after progression on or after platinum-based chemotherapy. * Have carcinomatous meningitis and/or non-carcinomatous meningitis central nervous system (CNS) metastasis apart from the following noted exceptions. Participants with previously treated brain metastases may participate provided they have stable CNS disease (ie, without evidence of progression) for at least 4 weeks (independent from completion of definitive treatment) prior to randomization and all neurologic symptoms have returned to baseline, have no evidence of new or enlarging brain metastases, and are taking ≤ 10 mg/day of prednisone or its equivalent. Participants with untreated, clinically stable brain metastases will be allowed if they are asymptomatic and the investigator determines there is no immediate CNS-specific treatment required, there is no surrounding edema, and the brain metastases are of 5 mm or less in size and 3 or fewer lesions. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Sacituzumab Govitecan (SG)

  • Group 2 · Studied intervention

    Topotecan · Amrubicin (Japan only) · Lurbinectedin (regions/countries where approved and available)

Start of the whole study
4 April 2025
Completion of the whole study
October 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Updated in the registry: 20 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07063745Phase 2Listed as recruiting

First-line metastatic lung cancer with MTAP deletion: navlimetostat added to pembrolizumab and chemotherapy

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 4 more cities

See all centres (11)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07063745. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0022

    +40 745 646 368

    Source: study registry

  • Institutul Oncologic Cluj

    Contact for this study

    Cristina Cebotaru

    Centre code in the registry: 0023

    +40 745 976 913

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0025

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0019

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0031

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0026

    +40 744 692 062

    Source: study registry

Otopeni

  • Radiology Therapeutic Center

    Contact for this study

    Elena Ciubotaru

    Centre code in the registry: 0027

    +40 723 171 603

    Source: study registry

Ploiești

  • Spitalul Municipal Schuller Ploiești

    Contact for this study

    Nita Amedeia

    Centre code in the registry: 0030

    +40 728 121 201

    Source: study registry

Who can take part

First-line metastatic lung cancer with MTAP deletion: navlimetostat added to pembrolizumab and chemotherapy

The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have Metastatic (Stage IV or recurrent) non-small cell lung cancer (NSCLC) (as defined by the American Joint Committee on Cancer, Ninth Edition) with no prior systemic anti-cancer therapy for metastatic disease. * Participants must have histologically confirmed diagnosis of NSCLC and homozygous methylthioadenosine phosphorylase (MTAP) deletion or MTAP loss. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Participants must have at least 1 measurable lesion as per RECIST v1.1. Exclusion Criteria * Nonsquamous participants must not have documented targetable oncogenic mutation or actionable genetic alterations (AGAs) for which there is a standard of care (SoC) available as first-line (1L) therapy. * Participants must not have symptomatic brain metastases or spinal cord compression. * Participants must not have any prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for metastatic non-small cell lung cancer (mNSCLC). Note: One cycle of SoC treatment prior to randomization will be allowed for participants who require immediate treatment if clinically indicated. * Participants must not have any known or suspected impairment of gastrointestinal function that may prohibit the ability to absorb or swallow an oral medication without chewing or crushing. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Active treatment comparison

    BMS-986504 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

  • Group 2 · Active treatment comparison

    BMS-986504 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

  • Group 3 · Placebo comparison

    Pembrolizumab · Placebo · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

  • Group 4 · Placebo comparison

    Pembrolizumab · Placebo · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

  • Group 5 · Active treatment comparison

    BMS-986504 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

  • Group 6 · Placebo comparison

    Pembrolizumab · Placebo · Cisplatin · Carboplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel

Start of the whole study
2 January 2026
Completion of the whole study
12 August 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Updated in the registry: 13 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07361510Phase 3Listed as recruiting

Untreated advanced lung cancer with high PD-L1: pumitamig compared with pembrolizumab

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Minimum age: 18 years

Centres in: Baloteşti · București · Cluj-Napoca · and 4 more cities

See all centres (10)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07361510. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Baloteşti

București

  • Centrul de Diagnostic si Tratament Provita

    Contact for this study

    Mircea Dediu

    Centre code in the registry: 0044

    +40 744 432 443

    Source: study registry

  • Spitalul Clinic Colțea

    Contact for this study

    Ileana-Raluca Patru

    Centre code in the registry: 0049

    +40 722 619 891

    Source: study registry

  • Spitalul Universitar de Urgență București

    Contact for this study

    Georgeta Iorga

    Centre code in the registry: 0136

    +40 721 245 891

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0209

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0084

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0132

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0127

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0068

    +40 744 692 062

    Source: study registry

Timișoara

  • Oncohelp Medical Center

    Contact for this study

    Daniela Sirbu

    Centre code in the registry: 0222

    +40 744 571 617

    Source: study registry

Who can take part

Untreated advanced lung cancer with high PD-L1: pumitamig compared with pembrolizumab

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC or Stage IV disease. * Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%. * Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. * Participants must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC. * Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Exclusion Criteria * Participants must not have any documented actionable genomic alteration (AGA) for which first-line (1L) approved therapies are indicated. * Participants must not have any symptomatic untreated central nervous system (CNS) metastases, leptomeningeal metastases (carcinomatous meningitis) or spinal cord compression. * Participants must not have any significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, or major thrombotic or embolic events or major hemorrhagic events (within 6 months prior to randomization), or significant risk of pulmonary hemorrhage. * Participants must not an active autoimmune disease. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pumitamig

  • Group 2 · Active treatment comparison

    Pembrolizumab

Start of the whole study
12 March 2026
Completion of the whole study
14 October 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Updated in the registry: 23 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT05920356Phase 3Listed as recruiting

First-line advanced non-squamous lung cancer: sotorasib with chemotherapy compared with pembrolizumab with chemotherapy

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT05920356. This contact may be in another country; ask which language you can use.

Amgen Call Center

866-572-6436 (dialling format unconfirmed)

medinfo@amgen.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Iași

Ploiești

Timișoara

Who can take part

First-line advanced non-squamous lung cancer: sotorasib with chemotherapy compared with pembrolizumab with chemotherapy

The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.

Minimum age:
18 years
Maximum age:
100 years
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of nonsquamous stage IV or advanced Stage IIIB or IIIC NSCLC with KRAS p. G12C mutation and negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing * No history of systemic anticancer therapy in metastatic/non-curable settings * Eastern Cooperative Oncology Group (ECOG) ≤ 1 Exclusion Criteria: * Mixed histology NSCLC with either small-cell or large-cell neuroendocrine cell component or predominant squamous cell histology * Participants with tumors known to harbor molecular alterations for which targeted therapy is locally approved as a front-line therapy * Symptomatic (treated or untreated) brain metastases * Gastrointestinal (GI) tract disease causing the inability to take oral medication * Myocardial infarction within 6 months of randomization, unstable arrhythmias, or unstable angina * Prior therapy with a KRAS G12C inhibitor

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Sotorasib

  • Group 2 · Active treatment comparison

    Pembrolizumab

Start of the whole study
16 November 2023
Completion of the whole study
29 June 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Updated in the registry: 13 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06345729Phase 3Listed as recruiting

KRAS G12C-mutated lung cancer with high PD-L1: calderasib alongside pembrolizumab

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Minimum age: 18 years

Centres in: Brașov · București · Cluj-Napoca · and 3 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06345729. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • SC ONCO CARD SRL

    Contact for this study

    Study Coordinator

    +40 268 994

    Source: study registry

București

  • Centrul de Diagnostic si Tratament Provita

    Contact for this study

    Study Coordinator

    +40 21 9432

    Source: study registry

  • SC MNT HEALTHCARE EUROPE SRL

    Contact for this study

    Study Coordinator

    +40 722 927 377

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj-Oncologie Medicala

    Contact for this study

    Study Coordinator

    +40 264 598 362

    Source: study registry

Craiova

  • Centrul de Oncologie Sfantul Nectarie-Medical

    Contact for this study

    Study Coordinator

    +40 731 604 432

    Source: study registry

Suceava

  • Sigmedical Services SRL

    Contact for this study

    Study Coordinator

    +40 330 803 483

    Source: study registry

Timișoara

  • Cabinet Medical Oncomed

    Contact for this study

    Study Coordinator

    +40 356 460 995

    Source: study registry

Who can take part

KRAS G12C-mutated lung cancer with high PD-L1: calderasib alongside pembrolizumab

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There is one primary study hypothesis: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC) * Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8 * Provides an archival tumor sample (≤5 years) or newly obtained core, incisional, or excisional biopsy or fine needle aspirate (FNA) of a tumor lesion, not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, programmed cell death ligand 1 (PD-L1) status, and biomarker research * If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to \< Grade 1 or baseline * If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART) * If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load * If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable Exclusion Criteria: * Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease * Has known history of, or active, neurologic paraneoplastic syndrome * Has an active infection requiring systemic therapy, with exceptions * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC * Has received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention * Has received radiotherapy to non-central nervous system (CNS) disease within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis * Has known active CNS metastases and/or carcinomatous meningitis * Known additional malignancy that is progressing or has required active treatment within the past 3 years * Has active autoimmune disease that has required systemic treatment in the past 2 years * Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has history of allogenic tissue/solid organ transplant * Has not fully recovered from any effects of major surgical procedure

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Calderasib · Pembrolizumab

  • Group 2 · Active treatment comparison

    Placebo · Pembrolizumab

Start of the whole study
24 May 2024
Completion of the whole study
18 February 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06561386Phase 3Listed as recruiting

Stage IV PD-L1-positive non-squamous lung cancer: nivolumab and relatlimab with chemotherapy compared with pembrolizumab with chemotherapy

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06561386. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • SC Memorial Healthcare International SRL

    Contact for this study

    Ingrid Iordan

    Centre code in the registry: 0296

    +40 721 298 677

    Source: study registry

  • Institutul Oncologic Bucuresti "Prof. Dr. Alexandru Trestioreanu"

    Contact for this study

    Aurelia Alexandru

    Centre code in the registry: 0298

    +40 723 289 606

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0301

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0295

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0299

    +40 742 206 212

    Source: study registry

Iași

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0300

    +40 744 692 062

    Source: study registry

Ploiești

  • Spitalul Municipal Schuller Ploiești

    Contact for this study

    Nita Amedeia

    Centre code in the registry: 0297

    +40 728 121 201

    Source: study registry

Who can take part

Stage IV PD-L1-positive non-squamous lung cancer: nivolumab and relatlimab with chemotherapy compared with pembrolizumab with chemotherapy

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease. * Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization. * Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria. * Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening. * Participants must have a life expectancy of at least 3 months at the time of randomization. Exclusion Criteria * Participants must not be pregnant and/or breastfeeding. * Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded. * Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible. * Participants must not have untreated central nervous system (CNS) metastases. * Participants must not have leptomeningeal metastases (carcinomatous meningitis). * Participants must not have concurrent malignancy requiring treatment. * Participants must not have an active autoimmune disease. * Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management. * Participants must not have a history of myocarditis. * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. Note: Anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy given in an adjuvant, neoadjuvant or perioperative setting with at least 6 months between the last dose and date of recurrence are allowed. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Nivolumab · Relatlimab · Carboplatin · Pemetrexed · Cisplatin

  • Group 2 · Active treatment comparison

    Pembrolizumab · Carboplatin · Pemetrexed · Cisplatin

Start of the whole study
7 October 2024
Completion of the whole study
4 August 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Updated in the registry: 9 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06712316Phase 2Listed as recruiting

Lung cancer: BNT327 alongside chemotherapy and other investigational medicines

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (13)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06712316. This contact may be in another country; ask which language you can use.

BioNTech clinical trials patient information

+4961319084

patients@biontech.de

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Iași

Ploiești

Timișoara

Who can take part

Lung cancer: BNT327 alongside chemotherapy and other investigational medicines

This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Key Inclusion Criteria: * Have systemic treatment naive, histologically or cytologically confirmed diagnosis of Stage IIIB or IIIC (who are not amenable to curative surgery or radiotherapy) or Stage IV NSCLC per the Union Internationale contre le Cancer/American Joint Committee on Cancer staging system, 9th edition. * Have at least one measurable lesion as the targeted lesion based on RECIST v1.1. Lesions treated after prior local treatment (radiotherapy, ablation, interventional procedures, etc.) are generally not considered as target lesions. If the lesion with prior local treatment is the only targeted lesion, evidence-based radiology must be provided to demonstrate disease progression (the single bone metastasis or the single central nervous system metastasis should not be considered as a measurable lesion). * Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Adequate organ function as defined in the protocol. Key Exclusion Criteria: * Have histologically or cytologically confirmed NSCLC with small-cell lung cancer or neuroendocrine histologic component. * Have received any of the following therapies or drugs within the noted time intervals prior to study treatment: * Previous chemotherapy (platinum-based) or PD(L)-1 for treating NSCLC in either neoadjuvant/adjuvant or locally advanced/metastatic setting. * Participants who received prior treatment with anti-VEGF monoclonal antibody, or PD(L)-1/VEGF bispecific antibody. * Have received systemic corticosteroids (at a dosage greater than 10 mg/day of prednisone or an equivalent dose of other corticosteroids) within 7 days prior to the initiation of study treatment. Note: local, intranasal, intraocular, intra-articular or inhaled corticosteroids, short-term use (\<=7 days) of corticosteroids for prophylaxis (e.g., prevention of contrast agent allergy) or treatment of non-autoimmune conditions (e.g., delayed hypersensitivity reactions caused by exposure to allergens) are allowed. * Have uncontrolled hypertension or poorly controlled diabetic conditions prior to study treatment. * Have a serious or non-healing wound, or (incompletely healed) bone fracture. This includes history (within 6 months prior to study entry) or risk of abdominal fistula, tracheoesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess or esophageal and gastric varices. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing fistula/perforation. * Participants with significant risk of hemorrhage (per investigator clinical judgment). * Participants have superior vena cava syndrome or symptoms of spinal cord compression. NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pumitamig · Carboplatin · Pemetrexed

  • Group 2 · Studied intervention

    Pumitamig · Carboplatin · Pemetrexed

  • Group 3 · Studied intervention

    Pumitamig · Carboplatin · Pemetrexed

  • Group 4 · Studied intervention

    Pumitamig · Carboplatin · Pemetrexed

  • Group 5 · Active treatment comparison

    Pembrolizumab · Carboplatin · Pemetrexed

  • Group 6 · Studied intervention

    Pumitamig · Carboplatin · Paclitaxel

  • Group 7 · Studied intervention

    Pumitamig · Carboplatin · Paclitaxel

  • Group 8 · Studied intervention

    Pumitamig · Carboplatin · Paclitaxel

  • Group 9 · Studied intervention

    Pumitamig · Carboplatin · Paclitaxel

  • Group 10 · Active treatment comparison

    Pembrolizumab · Carboplatin · Paclitaxel

Start of the whole study
7 January 2025
Completion of the whole study
December 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

Updated in the registry: 2 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06758401Phase 3Listed as recruiting

Lung cancer with high PD-L1: sigvotatug vedotin alongside pembrolizumab

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06758401. This contact may be in another country; ask which language you can use.

Pfizer CT.gov Call Center

1-800-718-1021 (dialling format unconfirmed)

ClinicalTrials.gov_Inquiries@pfizer.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Florești

Ovidiu

Timișoara

Who can take part

Lung cancer with high PD-L1: sigvotatug vedotin alongside pembrolizumab

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a protein that acts as a kind of "brake" to keep the body's immune responses under control. The study is seeking for participants who: * Are confirmed to have NSCLC (Stage 3 or 4). * Have PD-L1 levels in more than 50% of the cancer cells. All participants in this study will receive pembrolizumab at the study clinic once every 6 weeks as an intravenous (IV) infusion (give directly into a vein). In addition, half of the participants will also receive Sigvotatug Vedotin once every 2 weeks as an IV infusion in addition to receiving pembrolizumab. Participants may receive pembrolizumab for up to about two years. Those participants taking Sigvotatug Vedotin can continue until their NSCLC is no longer responding. The study team will monitorsee how each participant is doing with the study treatment during regular visits at the clinic.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Participants must meet the following criteria: 1. Have pathologically confirmed Stage IIIB or IIIC NSCLC and not be a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC per the AJCC Staging Manual (Version 8.0) and the UICC Staging System (Eighth edition). 2. Participants with known AGAs including EGFR, ALK, ROS1, NTRK, BRAF, RET, and MET, for which there are approved and available first-line therapies per local SOC are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology. 3. Participants with large cell neuroendocrine carcinoma are excluded. 4. Must be an appropriate candidate for treatment with pembrolizumab monotherapy per local guidelines. 2. Tumor has PD-L1 expression in ≥50% of tumor cells (TPS ≥50%) as determined by local testing. 3. Measurable disease based on RECIST v1.1 per investigator. 4. Resolution of acute effects of any prior therapy to either baseline severity or NCI CTCAE Grade 1 or less (except for AEs not constituting a safety risk in the investigator's judgment), unless otherwise excluded. Exclusion Criteria: 1. Life expectancy of \<3 months in the opinion of the investigator. 2. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study. 3. Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. 4. Known or suspected hypersensitivity, intolerance, or contraindication to any excipient contained in the drug formulation of sigvotatug vedotin or pembrolizumab. 5. Participants with any of the following respiratory conditions: 1. Evidence of noninfectious or drug-induced ILD or pneumonitis 2. Known DLCO (adjusted for hemoglobin) \<50% predicted. 3. Grade ≥3 pulmonary disease unrelated to underlying malignancy 6. Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Up to 5 clinically asymptomatic brain metastases of longest diameter \<1.0 cm are permitted without definitive surgery and/or radiotherapy. 7. Major surgery (defined as a surgery requiring inpatient hospitalization of at least 48 hours) within 21 days or minor surgery (excluding peripherally inserted central catheter placement and implantable central venous port placement) within 3 days prior to first dose of study intervention. 8. Receipt of a live vaccine within 30 days prior to first dose of study intervention. 9. Pre-existing peripheral neuropathy Grade ≥2 per NCI CTCAE v5.0. 10. Uncontrolled diabetes mellitus, defined as HbA1c ≥8.0% or HbA1c between 7.0% and 8.0% with associated diabetes symptoms (polyuria or polydipsia) that are not otherwise explained. 11. Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, required a high-dose steroid taper (≥0.5 mg/kg prednisone or equivalent per day) for \>2 weeks, or required treatment with systemic immunosuppressive therapy. 12. History of autoimmune disease that has required systemic treatment in the past 2 years 13. Participants with prior solid organ or bone marrow transplantation. 14. Currently receiving a high-dose steroid (\>10 mg prednisone or equivalent per day) or other immune suppressant or has a condition requiring a chronic high-dose steroid or immune suppressant. 15. Prior and concomitant therapy: 1. Any prior treatment with MMAE-derived drugs or IB6 targeting agents. 2. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC. * (Neo)adjuvant anti-PD-(L)1 is allowed if recurrence or progression occurred ≥9 months after the last dose. * Other (neo)adjuvant or definitive therapy is allowed if recurrence or progression occurred ≥6 months after the last dose. 3. Prior radiotherapy to the lung within 6 months of first dose of study intervention, referencing the last date radiotherapy was received. This includes both curative and palliative radiotherapy. 4. Chemotherapy, biologics, and/or other antitumor treatment with immunotherapy not specifically prohibited that is completed less than 4 weeks prior to first dose of study intervention, or 2 weeks for palliative radiotherapy. 5. Any prior therapy with an immune-oncology agent directed to a stimulatory or co-inhibitory T-cell receptor 16. History of or current ongoing infection, including participants positive for active HIV, HBV, or HCV. 17. Severe uncontrolled cardiac or cerebrovascular condition within the previous 6 months

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Sigvotatug Vedotin · Pembrolizumab

  • Group 2 · Active treatment comparison

    Pembrolizumab

Start of the whole study
23 July 2025
Completion of the whole study
1 March 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06868277Phase 3Listed as recruiting

First-line metastatic lung cancer with high PD-L1: rilvegostomig compared with pembrolizumab

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Minimum age: 18 years

Centres in: București · Craiova · Otopeni · and 3 more cities

See all centres (10)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06868277. This contact may be in another country; ask which language you can use.

AstraZeneca Clinical Study Information Center

1-877-240-9479 (dialling format unconfirmed)

information.center@astrazeneca.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Craiova

Otopeni

Pitești

Sibiu

Timișoara

Who can take part

First-line metastatic lung cancer with high PD-L1: rilvegostomig compared with pembrolizumab

The purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histologically or cytologically documented NSCLC (non small lung cancer), including all histological subtypes. * Stage IV mNSCLC (metastatic non-small cell lung cancer) (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment. * Absence of sensitizing EGFR (epidermal growth factor) mutations and ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) rearrangements. Negative assay result is required for all non-squamous histology subtypes. * Absence of documented tumor genomic mutation results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L (first line) therapies. * WHO (World Health Organization)/ECOG (Eastern Cooperative Oncology Group) performance status of 0 or 1, with no deterioration over the previous 2 weeks prior to baseline at screening and prior to randomization. * Minimum life expectancy of 12 weeks. * Provision of acceptable tumor sample for the central testing prior to randomization. * At least one lesion not previously irradiated that qualifies as a RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, Version 1.1) TL (target lesion) at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter (except lymph nodes, which must have short axis ≥ 15 mm) with CT (computed tomography) or MRI (magnetic resonance imaging) and is suitable for accurate repeated measurements. * Adequate organ and bone marrow function Exclusion Criteria: * As judged by the investigator, any severe or uncontrolled systemic diseases, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol. * History of organ transplant. * Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment. * History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. * Presence of small cell and neuroendocrine histology components. * Brain metastases unless asymptomatic, stable, and not requiring steroids or anticonvulsants for at least 4 weeks prior to start of study intervention. * Active primary immunodeficiency/active infectious disease(s) * Active tuberculosis infection * Any prior systemic therapy received for advanced or mNSCLC (metastatic non-small cell lung cancer). * Any prior exposure to an anti-TIGIT (T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain) therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms. * Any prior treatment with an anti-PD-1 (programmed cell death protein 1) or anti-PD-L1 (anti-programmed death-ligand 1) agent.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Rilvegostomig

  • Group 2 · Active treatment comparison

    Pembrolizumab

Start of the whole study
10 April 2025
Completion of the whole study
2 December 2030 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Updated in the registry: 25 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06875310Phase 3Listed as recruiting

Untreated non-squamous lung cancer with KRAS G12C mutation: adagrasib added to pembrolizumab and chemotherapy

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06875310. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • SC Memorial Healthcare International SRL

    Contact for this study

    Ingrid Iordan

    Centre code in the registry: 0272

    +40 721 298 677

    Source: study registry

  • Institutul Oncologic Bucuresti "Prof. Dr. Alexandru Trestioreanu"

    Contact for this study

    Aurelia Alexandru

    Centre code in the registry: 0261

    +40 723 289 606

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0273

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0271

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0268

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0266

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0260

    +40 744 692 062

    Source: study registry

Timișoara

  • Oncohelp Medical Center

    Contact for this study

    Daniela Sirbu

    Centre code in the registry: 0592

    +40 744 571 617

    Source: study registry

Who can take part

Untreated non-squamous lung cancer with KRAS G12C mutation: adagrasib added to pembrolizumab and chemotherapy

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of non-squamous NSCLC with evidence of KRAS G12C mutation via tumor sample and/or circulating tumor deoxyribonucleic acid (ctDNA). * Locally advanced or metastatic disease. * Measurable disease via computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria of at least 1 lesion. * No prior systemic anti-cancer therapy given for advanced or metastatic disease. * Not a candidate for definitive therapy (eg, chemoradiation or complete surgical resection). * Participants with brain metastases are eligible for enrollment, including those with untreated brain metastases. Brain metastases must be asymptomatic and not in need of immediate local therapy. Any untreated brain metastases must be ≤ 20 mm in diameter. * Any PD-L1 expression (0 to 100%) as determined by VENTANA PD-L1 (SP263) assay, Agilent PD-L1 IHC 22C3 pharmDx, or Agilent PD-L1 IHC 28-8 pharmDx. Exclusion Criteria: * Participants with an active autoimmune or inflammatory disease requiring systemic treatment within 2 years. * Uncontrolled or significant cardiovascular conditions within 6 months prior to enrollment that are ongoing or with risk of recurrence. * Inadequate bone marrow or liver function or electrocardiogram (ECG) abnormalities. * Ongoing treatment with concomitant medication known to cause prolonged QTc interval and that cannot be switched to alternative treatment prior to study entry. * Treatment targeting KRAS G12C mutation (eg, sotorasib, adagrasib) in any setting. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Adagrasib · Pembrolizumab · Carboplatin · Pemetrexed · Cisplatin

  • Group 2 · Placebo comparison

    Pembrolizumab · Carboplatin · Pemetrexed · Placebo · Cisplatin

Start of the whole study
24 April 2025
Completion of the whole study
30 April 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Updated in the registry: 17 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06899126Phase 3Listed as recruiting

First-line HER2-overexpressing lung cancer: trastuzumab deruxtecan with pembrolizumab and chemotherapy

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (9)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06899126. This contact may be in another country; ask which language you can use.

Contact for Trial Information

908-992-6400 (dialling format unconfirmed)

CTRinfo_us@daiichisankyo.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Lasi

Otopeni

Ploiești

Who can take part

First-line HER2-overexpressing lung cancer: trastuzumab deruxtecan with pembrolizumab and chemotherapy

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Sign and date the Tissue Screening ICF, prior to any Tissue Screening procedure. Sign and date the Main ICF, prior to the start of any trial-specific qualification procedures. Sign and date the Optional PGx ICF (included in the Main ICF) prior to any PGx procedure, and the Pregnant Partner ICF, if applicable. 2. Adults ≥18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is \>18 years old. 3. Histologically documented non-squamous locally advanced unresectable or metastatic NSCLC and meets all of the following criteria: Has Stage IV NSCLC disease or Stage IIIB or IIIC disease but is not a candidate for surgical resection or definitive chemoradiation at the time of randomization (based on the American Joint Committee on Cancer, Eighth Edition). Has no known AGAs (based on the local test results obtained using validated or approved tests as required per local regulation) that have locally available therapies targeting their AGAs in the first-line advanced/metastatic setting. Has no known HER2 mutation based on existing test results (if approved or validated local test is available). Note: Participants with mixed histology are eligible if non-squamous NSCLC is the predominant histology. Mixed tumors will be classified based on the predominant cell type. 4. Has not been treated with systemic anticancer therapy for advanced or metastatic non-squamous NSCLC. Participants who received adjuvant or neoadjuvant therapy other than those listed below, including ICI (ie, anti-PD-1/PD-L1) or a platinum-based regimen, are eligible if the last dose of adjuvant/neoadjuvant therapy was given at least 6 months before the date of the first trial dose if their disease has progressed at least 6 months after the last dose date of adjuvant/neoadjuvant therapy. 1. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I. 2. HER2-targeted antibody-based anticancer therapy. 5. Has adequate tumor tissue sample (not previously irradiated) available for assessment of HER2 and PD-L1 expression by central or Sponsor-specified laboratory. A new biopsy is required if the participant's most recent archival tumor tissue sample cannot be supplied. Details pertaining to tumor tissue submission can be found in the Trial Laboratory Manual. Exclusion Criteria: 1. Has a medical history of MI within 6 months before randomization/enrollment or symptomatic CHF (NYHA Class II to Class IV). Participants with troponin levels above the ULN at Screening (as defined by the manufacturer) and without any MI-related symptoms must be ruled out for MI. It is highly recommended that the investigator refer such participants for a cardiologic consultation during the Screening Period. 2. Has a QTc prolongation to \>480 ms based on the average of the Screening triplicate 12- lead ECG. 3. Has a history of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening. 4. Has clinically severe pulmonary compromise resulting from intercurrent, pulmonary illnesses including, but not limited to: 1. Any underlying pulmonary disorder (eg, pulmonary emboli within 3 months of the trial randomization, severe asthma, severe COPD, restrictive lung disease, pleural effusion). 2. Any auto immune, connective tissue, or inflammatory disorders with potential pulmonary involvement (eg, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis). Severe conditions are those defined as impacting daily activities and/or requiring use of supplemental oxygen. 5. Had a prior complete pneumonectomy.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Trastuzumab Deruxtecan · pembrolizumab

  • Group 2 · Active treatment comparison

    pembrolizumab · Pemetrexed · Platinum Chemotherapy

Start of the whole study
24 October 2025
Completion of the whole study
24 November 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Updated in the registry: 18 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07099898Phase 3Listed as recruiting

Relapsed small cell lung cancer: GSK5764227, a medicine under study

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

Minimum age: 18 years

Centres in: Cluj-Napoca · Craiova · Craiova Dolj · and 3 more cities

See all centres (6)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07099898. This contact may be in another country; ask which language you can use.

US GSK Clinical Trials Call Center

877-379-3718 (dialling format unconfirmed)

GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center

+44 2089904466

GSKClinicalSupportHD@gsk.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Cluj-Napoca

Craiova

Craiova Dolj

Florești

Iași

Timișoara

Who can take part

Relapsed small cell lung cancer: GSK5764227, a medicine under study

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understanding of the main side effects of both drugs. Participants with relapsed SCLC will be randomly divided into two groups: one group receiving Ris-Rez and the other receiving topotecan.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Adults \>18 or the minimum legal adult age at the time the informed consent form is signed * Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC). * Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of \>30 days, with documented progression. Participants with prior tarlatamab treatment in either the first- or second-line ES-SCLC setting are eligible. * Has at least 1 target lesion per RECIST 1.1, as determined by the investigator. * Is capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the ICF and in the protocol. * Has adequate organ function and an ECOG performance status of 0 or 1 Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: * Pathological diagnosis of complex SCLC or transformed SCLC. * Limited stage small cell lung cancer at diagnosis * Has received any prior therapy with an Antibody-drug conjugate (ADC) with a Topoisomerase-1 (TOPO1)-inhibitor payload or treatments targeting B7-H3. * Has known sensitivity to study intervention components or excipients or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the study. * Has severe, uncontrolled or active cardiovascular disorders. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Known active infectious diseases requiring systemic treatment or known Human immunodeficiency virus (HIV). * Has symptomatic brain metastases or untreated progression exclusively due to brain metastasis during or after the last treatment prior to screening, evidence of leptomeningeal/meningeal/brainstem metastasis or evidence of spinal cord metastases. * Has any evidence of current interstitial lung disease or pneumonitis or a prior history of ILD or non-infectious pneumonitis requiring high dose steroids. * Has significant pulmonary disease or respiratory impairment (e.g., uncontrolled asthma/COPD, restrictive lung disease), * Has active Hepatitis B or Hepatitis C

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Risvutatug rezetecan (Ris-Rez)

  • Group 2 · Active treatment comparison

    Topotecan

Start of the whole study
11 August 2025
Completion of the whole study
28 September 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

Updated in the registry: 10 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07190248Phase 3Listed as recruiting

Non-small cell lung cancer: calderasib and other treatments, tested across several groups

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Minimum age: 18 years

Centres in: Brașov · București · Cluj-Napoca · and 3 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07190248. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • SC ONCO CARD SRL

    Contact for this study

    Study Coordinator

    +40 268 960

    Source: study registry

București

  • Spitalul Clinic Colțea

    Contact for this study

    Study Coordinator

    +40 21 387 4100

    Source: study registry

  • SC MNT Healthcare Europe SRL

    Contact for this study

    Study Coordinator

    +40 31 630 0000

    Source: study registry

  • Delta Health Care SRL

    Contact for this study

    Study Coordinator

    +40 21 9977

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Prof. Dr. I Chiricuta

    Contact for this study

    Study Coordinator

    +40 264 598 362

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Study Coordinator

    +40 731 604 432

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala

    Contact for this study

    Study Coordinator

    +40 21 9368

    Source: study registry

Ploiești

  • Spitalul Municipal Schuller Ploiești

    Contact for this study

    Study Coordinator

    +40 244 544 444

    Source: study registry

Who can take part

Non-small cell lung cancer: calderasib and other treatments, tested across several groups

Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has nonsquamous NSCLC (Stage IIIB, Stage IIIC) not eligible for curative resection or chemoradiation or Stage IV: M1a, M1b, or M1c * If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART) Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements * Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea) * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease * Has a gastrointestinal disorder affecting absorption * Is HIV positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has received prior systemic anticancer therapy for their advanced or metastatic NSCLC * Has known additional malignancy that is progressing or has required active treatment within the past 3 years * Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis * Has active autoimmune disease that has required systemic treatment in the past 2 years * History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease * Has active infection requiring systemic therapy except those specified by protocol * Has history of stem cell/solid organ transplant * Has not adequately recovered from major surgery or has ongoing surgical complications

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Calderasib · Pembrolizumab (+) Berahyaluronidase alfa

  • Group 2 · Active treatment comparison

    Pembrolizumab (+) Berahyaluronidase alfa · Pemetrexed · Cisplatin · Carboplatin

Start of the whole study
8 October 2025
Completion of the whole study
6 August 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07361497Phase 3Listed as recruiting

Unresectable stage III lung cancer after chemoradiation: pumitamig compared with durvalumab

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07361497. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Centrul de Diagnostic si Tratament Provita

    Contact for this study

    Mircea Dediu

    Centre code in the registry: 0219

    +40 744 432 443

    Source: study registry

  • Spitalul Universitar de Urgență București

    Contact for this study

    Georgeta Iorga

    Centre code in the registry: 0046

    +40 721 245 891

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0168

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie Sf. Nectarie SRL

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0045

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0058

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0184

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0164

    +40 744 692 062

    Source: study registry

Timisoara, Timis

  • Oncomed

    Contact for this study

    Daniela Sirbu

    Centre code in the registry: 0037

    +40 744 571 617

    Source: study registry

Who can take part

Unresectable stage III lung cancer after chemoradiation: pumitamig compared with durvalumab

A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have a histologically- or cytologically-confirmed diagnoses of non-small cell lung cancer (NSCLC) with unresectable Stage III disease. * Participants must have received at least 2 cycles of platinum-based concurrent chemoradiotherapy (a total dose of radiation of at least 54 Gy). * Participants must have no progressive disease (PD) following treatment with concurrent chemoradiotherapy (CCRT). * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. Exclusion Criteria * Participants with non-squamous histology must not have documented Epidermal Growth Factor Receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangements. * Participants must not have an active autoimmune disease. * Participants must not have significant cardiovascular impairment such as uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, major thrombotic or embolic events or major hemorrhagic events within 6 months prior to randomization, or significant risk of pulmonary hemorrhage. * Participants must not have advanced/clinically significant lung disease (within 6 months prior to randomization) or history of interstitial lung disease (ILD) or pneumonitis requiring treatment with systemic steroids (≥ Grade 2), or current or suspected ILD or pneumonitis. * Participants must not have any prior anticancer therapy (outside of CCRT) for locally advanced Stage III disease. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pumitamig

  • Group 2 · Active treatment comparison

    Durvalumab

Start of the whole study
16 March 2026
Completion of the whole study
13 January 2034 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Updated in the registry: 5 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07680764Phase 2Listed as recruiting

First-line advanced lung cancer: imzokitug added to pumitamig and platinum chemotherapy

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 3 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07680764. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Institutul Oncologic "Prof. Dr. Alexandru Trestioreanu" Bucuresti (IOB)

    Contact for this study

    Aurelia Alexandru

    Centre code in the registry: 0076

    +40 723 289 606

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0008

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie Sf. Nectarie SRL

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0075

    +40 727 774 974

    Source: study registry

Florești

  • Amethyst Radiotherapy Center-Oncologie Medicala

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0114

    +40 742 206 212

    Source: study registry

Iași

  • Victoria Hospital (Centrul de oncologie Euroclinic SRL) (Centrul De Oncologie Medicala) (Euroclinic Onchology Center)

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0115

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie Iasi

    Contact for this study

    Dana Clement

    Centre code in the registry: 0116

    +40 744 692 062

    Source: study registry

Timisoara, Timis

  • Oncohelp

    Contact for this study

    Daniela Sirbu

    Centre code in the registry: 0113

    +40 744 571 617

    Source: study registry

Who can take part

First-line advanced lung cancer: imzokitug added to pumitamig and platinum chemotherapy

The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have histologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) (squamous or non-squamous) or recurrent unresectable disease per the American joint committee on cancer (AJCC) Staging System 9th edition. * Participants must have no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease. * Tumor tissue (fresh or archival) obtained within 5 months of enrollment (signing of informed consent) for each participant must be submitted by the site. * Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1. * Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Exclusion Criteria * Participants must not have any documented actionable genomic alterations (AGAs) for which first line approved targeted therapies are indicated. * Participants must not have prior treatment with immuno-oncology therapies. * Participants must not have untreated central nervous system (CNS) metastases. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pumitamig · Imzokitug · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel

  • Group 2 · Studied intervention

    Pumitamig · Imzokitug · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel

  • Group 3 · Studied intervention

    Pumitamig · Imzokitug · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel

  • Group 4 · Studied intervention

    Pumitamig · Pemetrexed · Cisplatin · Carboplatin · Paclitaxel

Start of the whole study
10 September 2026
Completion of the whole study
15 September 2030 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Updated in the registry: 23 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT04613596Phase 2Listed as recruiting

KRAS G12C-mutated lung cancer: adagrasib alone and with pembrolizumab

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Florești · and 2 more cities

See all centres (5)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT04613596. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Institutul Oncologic Bucuresti - Prof. Dr. Alexandru Trestioreanu

    Contact for this study

    Aurelia Alexandru, Site 007-342

    +40 723 289 606

    Source: study registry

Cluj-Napoca

  • Medisprof

    Contact for this study

    Anghel-Adrian Udrea, Site 007-340

    +40 372 752 743

    Source: study registry

Florești

  • Centrul de Radioterapie Amethyst Cluj

    Contact for this study

    Andrei Ungureanu, Site 007-518

    +40 742 206 212

    Source: study registry

Iași

  • Centrul de Oncologie Euroclinic

    Contact for this study

    Constantin Volovat, Site 007-513

    +40 746 110 096

    Source: study registry

Timișoara

Who can take part

KRAS G12C-mutated lung cancer: adagrasib alone and with pembrolizumab

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Phase 2: Histologically confirmed diagnosis of unresectable or metastatic NSCLC with KRAS G12C mutation and any PD-L1 TPS * Phase 3: Histologically confirmed diagnosis of unresectable or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS\>=50% * Phase 3: Presence of measurable disease per RECIST1.1 * Phase 3: CNS Inclusion - Based on screening brain imaging, patients must have one of the following: 1. No evidence of brain metastases 2. Untreated brain metastases not needing immediate local therapy 3. Previously treated brain metastases not needing immediate local therapy Exclusion Criteria: * Phase 2 and Phase 3: Prior systemic treatment for locally advanced or metastatic NSCLC including chemotherapy, immune checkpoint inhibitor therapy, or a therapy targeting KRAS G12C mutation (e.g., AMG 510). * Phase 2: Active brain metastases * Phase 3: Patients with known central nervous system (CNS) lesions must not have any of the following: 1. Any untreated brain lesions \> 2.0 cm in size 2. Any brainstem lesions 3. Ongoing use of systemic corticosteroids for control of symptoms of brain lesions at a total daily dose of \> 10 mg of prednisone (or equivalent) prior to randomization. 4. Have poorly controlled (\> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain lesions notwithstanding CNS-directed therapy * Phase 3: Radiation to the lung \> 30 Gy within 6 months prior to the first dose of study treatment

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Adagrasib

  • Group 2 · Studied intervention

    Adagrasib

  • Group 3 · Studied intervention

    Adagrasib

  • Group 4 · Studied intervention

    Adagrasib

  • Group 5 · Active treatment comparison

    Pembrolizumab

Start of the whole study
2 December 2020
Completion of the whole study
31 October 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Updated in the registry: 19 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06119581Phase 3Listed as recruiting

First-line advanced KRAS G12C-mutated lung cancer: olomorasib and pembrolizumab, with or without chemotherapy

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 2 more cities

See all centres (8)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06119581. This contact may be in another country; ask which language you can use.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559 (dialling format unconfirmed)

LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Lotus-Med

    Contact for this study

    Anca Zgura

    Source: study registry

  • SC Memorial Healthcare International SRL

    Contact for this study

    Ingrid Iordan

    Source: study registry

  • Gral Medical Diagnostic Center

    Contact for this study

    Cristina Tiut

    Source: study registry

Cluj-Napoca

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Source: study registry

Ovidiu

  • Ovidius Clinical Hospital OCH

    Contact for this study

    Laura Mazilu

    Source: study registry

Timișoara

  • S C Oncocenter Oncologie Clinica S R L

    Contact for this study

    Roxana Scheusan

    Source: study registry

  • Cabinet Medical Oncomed

    Contact for this study

    Mihaela Pasca-Fenesan

    Source: study registry

Who can take part

First-line advanced KRAS G12C-mutated lung cancer: olomorasib and pembrolizumab, with or without chemotherapy

The purpose of this study is to assess if adding LY3537982 (olomorasib) in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KRAS G12C. Study participation, including follow-up, could last up to 3 years, depending on how you and your lung cancer are doing.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy. * Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label). * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Part A: Greater than or equal to (≥)50 percent (%). * Part B: 0% to 100%. * Part C: \<50%. * Must have measurable disease per RECIST v1.1. * Must have an ECOG performance status of 0 or 1. * Estimated life expectancy ≥12 weeks. * Ability to swallow capsules. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment Exclusion Criteria: * Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3. * Have had any of the following prior to randomization: \-- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC. \--- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated: * Have known active central nervous system metastases and/or carcinomatous meningitis. Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B) * Have predominantly squamous cell histology for NSCLC * Only for participants with mild to moderate renal insufficiency: Unable to avoid aspirin, ibuprofen, or other nonsteroidal anti-inflammatory drugs (NSAIDs) two days before (5 days for long acting NSAIDs), day of, and two days after administration of pemetrexed * Is unable or unwilling to take folic acid or vitamin B12 supplementation.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    LY3537982 · Pembrolizumab

  • Group 2 · Studied intervention

    LY3537982 · Pembrolizumab

  • Group 3 · Studied intervention

    LY3537982 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed

  • Group 4 · Studied intervention

    LY3537982 · Pembrolizumab

  • Group 5 · Placebo comparison

    Pembrolizumab · Placebo

  • Group 6 · Studied intervention

    LY3537982 · Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed

  • Group 7 · Placebo comparison

    Pembrolizumab · Placebo · Cisplatin · Carboplatin · Pemetrexed

  • Group 8 · Studied intervention

    LY3537982 · Pembrolizumab

Start of the whole study
21 December 2023
Completion of the whole study
January 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Updated in the registry: 4 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06312137Phase 3Listed as recruiting

Resectable non-small cell lung cancer without complete response: pembrolizumab with or without sacituzumab tirumotecan

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Minimum age: 18 years

Centres in: Brașov · București · Florești · and 2 more cities

See all centres (9)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06312137. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • SC ONCO CARD SRL

    Contact for this study

    Study Coordinator

    +40 268 960

    Source: study registry

București

  • MEMORIAL HEALTHCARE INTERNATIONAL S.R.L.

    Contact for this study

    Study Coordinator

    +40 31 9393

    Source: study registry

  • Institutul Oncologic Bucuresti Prof.Dr. Alex. Trestioreanu

    Contact for this study

    Study Coordinator

    +40 21 227 1000

    Source: study registry

  • SC MNT HEALTHCARE EUROPE SRL

    Contact for this study

    Study Coordinator

    +40 21 9230

    Source: study registry

  • Delta Health Care SRL

    Contact for this study

    Study Coordinator

    +40 21 9977

    Source: study registry

  • Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu

    Contact for this study

    Study Coordinator

    +40 21 316 1600

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL-Oncologie Medicala

    Contact for this study

    Study Coordinator

    +40 21 9368

    Source: study registry

Iași

  • Institutul Regional de Oncologie

    Contact for this study

    Study Coordinator

    +40 374 278 811

    Source: study registry

Timișoara

  • Spitalul Clinic Municipal De Urgenta Timisoara

    Contact for this study

    Study Coordinator

    +40 256 200 048

    Source: study registry

Who can take part

Resectable non-small cell lung cancer without complete response: pembrolizumab with or without sacituzumab tirumotecan

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

The key inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: * Has histological or cytological confirmation of squamous or nonsquamous non-small cell lung cancer (NSCLC), resectable clinical Stage II, IIIA or IIIB (with nodal involvement \[N2\]) per AJCC eighth edition guidelines * Has confirmation that either epidermal growth factor receptor (EGFR)-directed or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated as primary therapy * Is able to undergo surgery based on opinion of investigator after consultation with surgeon * Is able to receive neoadjuvant pembrolizumab and platinum-based doublet chemotherapy * Applies to screening for the adjuvant period only, before randomization: Has not achieved pathological complete response (pCR) at surgery by local review of pathology. * Applies to screening for the adjuvant period only, before randomization: Tumor tissue sample from surgical resection has been provided for determination of programmed cell death ligand 1 (PD-L1) and trophoblast cell surface antigen 2 (TROP2) status by central vendor before randomization into the adjuvant period * Applies to screening for the adjuvant period only, before randomization: Confirmed to be disease-free based on re-baseline radiological assessment as documented by contrast enhanced chest/abdomen/pelvis computed tomography (CT) (or magnetic resonance imaging (MRI)) within 28 days before randomization * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement are eligible * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load at screening * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at least 4 weeks before the start of study intervention Exclusion Criteria: * Has one of the following tumor locations/types: * NSCLC involving the superior sulcus * Large cell neuro-endocrine cancer (LCNEC) * Sarcomatoid tumor * Diagnosis of SCLC or, for mixed tumors, presence of small cell elements * Has Grade ≥2 peripheral neuropathy * Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing * Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease * Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QT corrected for heart rate by Fridericia's cube root formula (QTcF) interval to \>480 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention * Has received prior neoadjuvant therapy for their current NSCLC diagnosis * Has received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention * Has received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed * Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication * Has a known additional malignancy that is progressing or has required active treatment within the past 5 years * Has an active autoimmune disease that has required systemic treatment in the past 2 years * Has a history of (noninfectious) interstitial lung disease (ILD)/pneumonitis, has current ILD/pneumonitis, or has suspected ILD or pneumonitis that cannot be ruled out by standard diagnostic assessments at screening * Has an active infection requiring systemic therapy * Is an HIV-infected participant with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease * Has a concurrent active Hepatitis B (defined as HBsAg positive and/or detectable HBV deoxyribonucleic acid (DNA)) and Hepatitis C virus (defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid (RNA)) infection * Has a history of allogeneic tissue/solid organ transplant * Has not adequately recovered from major surgery or have ongoing surgical complications * Severe hypersensitivity (≥Grade 3) to study intervention, any of its excipients, and/or to another biologic therapy

What taking part involves

Group assignment is not random. The team explains the assignment specified in the protocol.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Sacituzumab tirumotecan · Pembrolizumab · Rescue medication

  • Group 2 · Active treatment comparison

    Pembrolizumab · Cisplatin · Pemetrexed · Gemcitabine · Carboplatin · Paclitaxel

Start of the whole study
3 April 2024
Completion of the whole study
23 October 2034 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Updated in the registry: 10 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06855771Phase 2Listed as recruiting

Previously treated advanced lung cancer with MTAP deletion: navlimetostat

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova · and 2 more cities

See all centres (7)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06855771. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

  • Institutul Oncologic Bucuresti "Prof. Dr. Alexandru Trestioreanu"

    Contact for this study

    Aurelia Alexandru

    Centre code in the registry: 0029

    +40 723 289 606

    Source: study registry

  • Centrul de Diagnostic si Tratament Provita

    Contact for this study

    Mircea Dediu

    Centre code in the registry: 0040

    +40 744 432 443

    Source: study registry

Cluj-Napoca

  • Institutul Oncologic Cluj

    Contact for this study

    Tudor Ciuleanu

    Centre code in the registry: 0034

    +40 745 646 368

    Source: study registry

Craiova

  • Centrul de Oncologie "Sfântul Nectarie"

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0031

    +40 727 774 974

    Source: study registry

Florești

  • SC Radiotherapy Center Cluj SRL

    Contact for this study

    Andrei Ungureanu

    Centre code in the registry: 0036

    +40 742 206 212

    Source: study registry

Iași

  • S.C. Centrul de Oncologie Euroclinic S.R.L.

    Contact for this study

    Constantin Volovat

    Centre code in the registry: 0030

    +40 746 110 096

    Source: study registry

  • Institutul Regional de Oncologie

    Contact for this study

    Dana Clement

    Centre code in the registry: 0032

    +40 744 692 062

    Source: study registry

Who can take part

Previously treated advanced lung cancer with MTAP deletion: navlimetostat

The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with homozygous MTAP deletion or MTAP loss after progression on prior therapies.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation. * Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition). * At least 1 measurable lesion as per RECIST v1.1. * Documented radiographic disease progression on or after the most recent line of treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Participant must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF. * Capability to swallow tablets intact (without chewing or crushing). * For combination arms 1. Participants must have documented evidence of EGFR status. 2. Participants with EGFR mutant or wild type NSCLC are allowed. Exclusion Criteria * Active brain metastases or carcinomatous meningitis. * History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. * Prior treatment with a PRMT5 or MAT2A inhibitor. * Known severe hypersensitivity to study treatment and/or any of its excipients. * For combination arms a. Prior therapy with iza-bren or any other antibody and/or ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload, except amivantamab. * Other protocol-defined inclusion/exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    BMS-986504

  • Group 2 · Studied intervention

    BMS-986504

  • Group 3 · Studied intervention

    BMS-986504 · Izalontamab Brengitecan

  • Group 4 · Studied intervention

    BMS-986504 · Izalontamab Brengitecan

Start of the whole study
9 September 2025
Completion of the whole study
30 December 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Updated in the registry: 18 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06623422Phase 3Listed as recruiting

Non-small cell lung cancer: pembrolizumab with or without intismeran autogene

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Minimum age: 18 years

Centres in: Brașov · București · Iași · and one more city

See all centres (4)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06623422. This contact may be in another country; ask which language you can use.

Toll Free Number

1-888-577-8839 (dialling format unconfirmed)

Trialsites@msd.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Brașov

  • S.C. ONCO CARD S.R.L

    Contact for this study

    Study Coordinator

    +40 268 960

    Source: study registry

București

Iași

  • Institutul Regional de Oncologie

    Contact for this study

    Study Coordinator

    +40 374 278 810

    Source: study registry

Timișoara

  • Cabinet Medical Oncomed

    Contact for this study

    Study Coordinator

    +40 256 495 403

    Source: study registry

Who can take part

Non-small cell lung cancer: pembrolizumab with or without intismeran autogene

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has histologically/cytologically confirmed diagnosis of previously untreated and pathologically confirmed resectable clinical Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC) \[American Joint Committee on Cancer (AJCC) 8th Edition\] * Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days before the first dose of study intervention * Participants who have not achieved a pathological complete response (pCR) following completion of neoadjuvant chemotherapy and pembrolizumab followed by surgery will be eligible * Confirmation that epidermal growth factor receptor (EGFR)-directed therapy is not indicated as primary therapy (documentation of absence of tumor-activating EGFR mutations \[eg, DEL19 or L858R\]) * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to randomization * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Diagnosis of small cell lung cancer (SCLC) or, for mixed tumors, presence of small cell elements, or has a neuroendocrine tumor with large-cell components, or a sarcomatoid carcinoma, or a pancoast tumor * Documentation by local test report indicating presence of anaplastic lymphoma kinase (ALK) gene rearrangements * Received prior neoadjuvant therapy for their current NSCLC diagnosis * Received prior therapy with an anti-programmed cell death 1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell-death ligand 2 (PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (eg, cytotoxic T-lymphocyte-associated protein \[CTLA-4\], OX-40, CD137) * Received prior systemic anticancer therapy including investigational agents other than what is specified in this protocol * Received prior treatment with a cancer vaccine * Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids * Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Gemcitabine · Paclitaxel · Intismeran autogene

  • Group 2 · Active treatment comparison

    Pembrolizumab · Cisplatin · Carboplatin · Pemetrexed · Gemcitabine · Paclitaxel · Placebo

Start of the whole study
21 October 2024
Completion of the whole study
26 January 2038 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Updated in the registry: 17 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07098988Phase 2Listed as recruiting

First-line metastatic lung cancer: visugromab added to immunochemotherapy

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Minimum age: 18 years

Centres in: Craiova · Pitești · Sibiu · and one more city

See all centres (4)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07098988. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Craiova

Pitești

Sibiu

Timișoara

Who can take part

First-line metastatic lung cancer: visugromab added to immunochemotherapy

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemotherapy (ICT: Pembrolizumab, Pemetrexed, Carboplatin) in the first-line treatment of participants with newly diagnosed metastatic non-squamous NSCLC. The trial consists of 3 Parts, a non-randomized Safety-run-in part (Part A) and the subsequent randomized Ph2b trial with 2 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Main Inclusion Criteria: * Histologically confirmed, newly diagnosed stage IV non-squamous NSCLC. * Demonstrated absence of actionable mutations (e.g., EGFR, ALK, among others) that suggest/require treatment with available targeted agent. * Measurable disease determined by the local site Investigator/radiology by their assessment per RECIST v1.1. * Have not received prior systemic treatment for advanced/metastatic NSCLC. Participants who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease and did not contain any PD 1/PD L1 directed CPI therapy. * Availability of locally determined PD L1 TPS, determined with a test validated for this purpose, from a tumor tissue biopsy obtained after any potential prior systemic treatment for this disease. Participants with PD-L1 TPS ≥ 50% can only be enrolled in case CPI monotherapy is not clinically indicated. * Availability of a tissue/histological biopsy for translational research investigations and Informed Consent Form (ICF) for biopsy release for translational research signed by participant. The biopsy has to be obtained after any potential prior systemic treatment for this disease and be available for shipment. A cytological sample is not accepted. * Age ≥ 18 years on the day of signing the informed consent. * Eastern Cooperative Oncology Group (ECOG) performance status 0-1. * Adequate organ function (bone marrow, hepatic, renal function and coagulation). Main Exclusion Criteria: * Presence of predominantly squamous cell histology or predominantly neuroendocrine histology NSCLC (mixed tumors will be categorized by the predominant cell type) or presence of small cell lung cancer elements (ineligibility independent of percentage). * Any acute or chronic major tissue injury that may require maintained GDF 15 function for tissue protection as per Investigator assessment (diagnosed with myocardial infarction, or liver, kidney or other major organ failure, all within \< 3 months prior to planned treatment start). * Major surgery (defined as a surgery which requires general anesthetic and/or involves opening of body cavities), within 4 weeks of the first dose of study drug. * Received potentially curative radiation therapy to the lung that is \> 30 Gy within 6 months prior to the first dose of study drug. * Received or completed any focal radiotherapy for symptoms within 28 days of the first dose of study drug. * Expected to require any other form of antineoplastic therapy while on trial. * Clinically active inflammatory bowel disease, active diverticulitis, intra-abdominal abscess, and/or gastrointestinal obstruction. * Known history of prior malignancy with the exception that the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. * Known or detected clinically active central nervous system (CNS) involvement by NSCLC or other tumors, e.g., with symptomatic metastases and/or carcinomatous meningitis. Participants with CNS involvement may be enrolled with mandatory regular imaging of the brain under protocol-defined conditions. * Have one of the following cardiovascular risk factors: myocardial infarction in the past 3 months before planned treatment start; uncontrolled heart failure; uncontrolled ventricular arrhythmia; QT interval corrected for heart rate using Fridericia's formula interval ≥ 470 ms regardless of sex; peri/myocarditis in the past 3 months before planned treatment start; history of ischemic stroke in the past 3 months before planned treatment start. * Any active autoimmune that has required systemic treatment in the past 3 months before planned treatment start (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). * Comedication with metformin or metformin-containing antidiabetics in participants with type II diabetes. * Has interstitial lung disease or a history of non-infectious pneumonitis that required systemic steroids or current pneumonitis. * Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Visugromab · Pembrolizumab 200 mg Q3W · Pemetrexed 500 mg/m^2 · Carboplatin AUC 5

  • Group 2 · Active treatment comparison

    Matching placebo for visugromab · Pembrolizumab 200 mg Q3W · Pemetrexed 500 mg/m^2 · Carboplatin AUC 5

Start of the whole study
1 August 2025
Completion of the whole study
31 March 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Updated in the registry: 19 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06472245Phase 3Listed as recruiting

Lung cancer with secondary resistance to immunotherapy: OSE2101, a therapeutic vaccine

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Minimum age: 18 years

Centres in: Cluj-Napoca · Craiova · Timișoara

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06472245. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Cluj-Napoca

Craiova

Timișoara

Who can take part

Lung cancer with secondary resistance to immunotherapy: OSE2101, a therapeutic vaccine

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Male or female, aged ≥ 18 years 2. Patients expressing HLA-A2 phenotype in blood by pre-screening central laboratory 3. Patients with histologically or cytologically squamous or non-squamous documented NSCLC, metastatic stage at study entry, not eligible for definite surgery or radiation, without EGFR, ALK and ROS1 gene alterations eligible for targeted therapy; for patients with squamous NSCLC, the molecular tests are not mandatory if age ≥ 50 years old and smoker ≥ 15 pack years; other sensitizing mutations known to be immunosensitive are eligible in case of lack of local access to targeted therapy (i.e.; KRAS G12C and BRAF mutations) after Sponsor' agreement. 4. Patients with secondary resistance to ICI; Other inclusion and exclusion criteria will apply per protocol.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    OSE2101 · NGS HLAA2 assay

  • Group 2 · Active treatment comparison

    Docetaxel · NGS HLAA2 assay

  • Group 3 · Group described in the registry

    NGS HLAA2 assay

Start of the whole study
3 December 2024
Completion of the whole study
15 December 2028 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

Updated in the registry: 12 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06772623Phase 1Listed as recruiting

Untreated advanced non-squamous lung cancer without targetable mutations: telisotuzumab adizutecan with immunotherapy

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Sibiu

See all centres (6)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06772623. This contact may be in another country; ask which language you can use.

ABBVIE CALL CENTER

844-663-3742 (dialling format unconfirmed)

abbvieclinicaltrials@abbvie.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Sibiu

Who can take part

Untreated advanced non-squamous lung cancer without targetable mutations: telisotuzumab adizutecan with immunotherapy

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Telisotuzumab Adizutecan (ABBV-400) and budigalimab are investigational drugs being developed for the treatment of NSCLC. This study will be divided into two stages, with the first stage treating participants with several doses of telisotuzumab adizutecan in combination with budigalimab within the dose escalation regimen until the dose reached is tolerable and expected to be efficacious. In Stage 2 there will be 3 treatment groups. Two groups will receive pembrolizumab with different optimized doses of telisotuzumab adizutecan (to allow for the best dose to be studied in the future). One group will receive the standard of care (SOC) - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. Approximately 252 adult participants with NSCLC will be enrolled in the study in 132 sites worldwide. In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of Telisotuzumab Adizutecan in combination with budigalimab until the dose of Telisotuzumab Adizutecan reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive IV optimized doses of Telisotuzumab Adizutecan in combination with IV pembrolizumab, or IV SOC - pembrolizumab, pemetrexed, and investigator's choice of carboplatin or cisplatin, followed by pembrolizumab and pemetrexed. The study will run for a duration of approximately 33 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. * Must have measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1. * For Part 1, participants must have had no more than 1 systemic therapy for advanced disease including platinum-based chemotherapy or an immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy), or appropriate targeted therapy for an actionable gene alteration, if applicable, for epidermal growth factor receptor (EGFR) wild-type (WT) NSq NSCLC. * For Part 2, participants must have no prior systemic therapy for advanced disease, no known actionable genomic alteration. * Must have documented programmed death ligand 1 (PD-L1) status. * For Part 2, participant must have evaluable c-Met immunohistochemistry (IHC) result per central testing prior to randomization. * Must have adequate organ function. Exclusion Criteria: * Known uncontrolled metastases to the central nervous system. * History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis on screening chest computed tomography (CT) scan.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Telisotuzumab Adizutecan · Budigalimab

  • Group 2 · Studied intervention

    Telisotuzumab Adizutecan · Pembrolizumab

  • Group 3 · Studied intervention

    Telisotuzumab Adizutecan · Pembrolizumab

  • Group 4 · Studied intervention

    Pembrolizumab · Carboplatin · Pemetrexed · Cisplatin

Start of the whole study
6 March 2025
Completion of the whole study
November 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Updated in the registry: 19 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06890598Phase 3Listed as recruiting

Resected or unresectable KRAS G12C-mutated lung cancer: olomorasib added to standard care

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Ovidiu

See all centres (4)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06890598. This contact may be in another country; ask which language you can use.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

1-317-615-4559 (dialling format unconfirmed)

LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Ovidiu

  • Ovidius Clinical Hospital OCH

    Contact for this study

    Laura Mazilu

    Source: study registry

Who can take part

Resected or unresectable KRAS G12C-mutated lung cancer: olomorasib added to standard care

The main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab is more effective than the durvalumab and placebo combination in part B in participants with unresectable KRAS G12C-mutant non-small cell lung cancer. The study may last up to 3 years for each participant.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Histological or cytological confirmation of NSCLC. * Part A 1. Clinical Stage II-IIIB (N0, N1, N2) treated with presurgical chemoimmunotherapy, with residual tumor present at time of surgery. Patients with a pathologic complete response are not eligible. 2. Pathologic Stage II-IIIB (N0, N1, N2) NSCLC treated with initial upfront resection. * Part B - Clinical Stage III, unresectable NSCLC, without progression on concurrent platinum-based chemoradiotherapy. * Must have disease with evidence of KRAS G12C mutation. * Must have known programmed death-ligand 1 (PD-L1) expression * Must have an ECOG performance status of 0 or 1. * Able to swallow oral medication. * Must have adequate laboratory parameters. * Contraceptive use should be consistent with local regulations for those participating in clinical studies. * Women of childbearing potential must * Have a negative pregnancy test. * Not be breastfeeding during treatment Exclusion Criteria: * Have known, actionable changes in the EGFR or ALK genes. * Have another type of cancer that is progressing or required active treatment within the past 2 years before screening. * Have an active autoimmune disease that required systemic treatment in the past 2 years. Endocrine replacement therapy is allowed. * Had any immune-related side effect or allergic reaction (Grade 3 or higher) from a previous immunotherapy medicine, or any immune-related side effect greater than Grade 1 that has not resolved. This does not apply for people with hormone-related diseases who are now on stable hormone replacement therapy.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Olomorasib · Pembrolizumab

  • Group 2 · Placebo comparison

    Pembrolizumab · Placebo

  • Group 3 · Studied intervention

    Olomorasib · Durvalumab

  • Group 4 · Placebo comparison

    Durvalumab · Placebo

Start of the whole study
27 March 2025
Completion of the whole study
February 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Updated in the registry: 4 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07128199Phase 3Listed as recruiting

Early lung cancer with uncommon EGFR mutations, after surgery: zipalertinib compared with placebo

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Minimum age: 18 years

Centres in: București · Ovidiu · Timișoara

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07128199. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Ovidiu

Timișoara

Who can take part

Early lung cancer with uncommon EGFR mutations, after surgery: zipalertinib compared with placebo

The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology. 2. Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[US\]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt: 1. exon20 insertion mutations (ex20ins) or 2. other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I) exons 18-21 of the EGFR tyrosine kinase domain 3. Baseline imaging assessment of the brain (MRI \[preferred modality\] or CT scan) performed within 8 weeks prior to randomization must show no evidence of brain metastasis 4. Complete surgical resection of the primary NSCLC is mandatory with negative surgical margins and systematic lymph node sampling or dissection. 5. Complete recovery from surgery, including post-operative wound healing, and prior adjuvant chemotherapy (if applicable) at the time of randomization. Randomization timing is defined as follows: 1. For participants without prior adjuvant chemotherapy: 4 weeks and 12 weeks following surgery. 2. For participants with prior adjuvant chemotherapy: 4 weeks and 8 weeks after the last dose of adjuvant chemotherapy. 6. Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1. 7. Pathologic (post-operative) Stage IB, IIA, IIB, or IIIA according to the AJCC 9th tumor nodes metastasis (TNM) staging system for lung cancer. In addition, participants with stage IIIB are eligible when regional lymph node involvement is N2. 8. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers. Exclusion Criteria: 1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research. 2. Treatment with any of the following within the time frame specified: 1. Zipalertinib (TAS6417/CLN-081) or any other EGFR inhibitor at any time. 2. Pre-operative or post-operative or planned radiation therapy for the current lung cancer. 3. Any prior systemic anticancer therapy for NSCLC, including preoperative (neoadjuvant) chemotherapy, immunotherapy, or investigational therapy. (Exception: Participants who have received postoperative adjuvant platinum-based chemotherapy up to 4 cycles are permitted) 4. Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks prior to the first dose of study treatment. 5. Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known. 3. Has received only wedge resections (complete anatomic segmentectomy is acceptable). 4. Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis or any evidence of clinically active ILD/pneumonitis. 5. Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior significant bowel resection). 6. Has a history of any other cancer except for any of the following: 1. Non-melanoma skin cancer treated with curative intent 2. Carcinoma in situ treated with curative intent 3. Other curatively treated cancer, with no evidence of disease for \>3 years following the end of treatment and, in the opinion of the treating physician, has no substantial risk of recurrence. 4. Concurrent malignancy of which natural history does not have the potential to interfere with the safety or efficacy assessment (eg, Gleason 6 prostate cancer) 7. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment. 8. Active bleeding disorders. 9. Known hypersensitivity to the ingredients in zipalertinib/placebo or any drugs similar in structure or class.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    TAS6417

  • Group 2 · Placebo comparison

    Zipalertinib Matching-placebo

Start of the whole study
22 December 2025
Completion of the whole study
1 October 2032 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Updated in the registry: 13 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07246863Phase 2Listed as recruiting

Second-line metastatic lung cancer: visugromab and nivolumab, with or without docetaxel

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Minimum age: 18 years

Centres in: Craiova · Sibiu · Timișoara

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07246863. This contact may be in another country; ask which language you can use.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Craiova

Sibiu

Timișoara

Who can take part

Second-line metastatic lung cancer: visugromab and nivolumab, with or without docetaxel

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor). The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Main Inclusion Criteria: * Participants must have histologically or cytologically confirmed diagnosis of stage IV non-squamous NSCLC. * Participants must have demonstrated absence of actionable mutations (e.g. EGFR, ALK, among others) that suggest/require treatment with available targeted agent. * Participants must have failed one line of prior systemic treatment for metastatic NSCLC containing an approved anti PD (L)1 checkpoint inhibitor (CPI). The minimum treatment duration on this regimen must have been 12 weeks exposure for the CPI with no documented progression in this period. Failure of the prior line of systemic treatment for metastatic NSCLC must have occurred under ongoing CPI treatment. Discontinuation of the prior CPI and line of treatment due to AEs, or any other reason than progression/relapse does not permit enrollment. * Participants must have measurable disease determined by the local site Investigator by their assessment per RECIST v1.1. * Participants must have life expectancy of at least 3 months as assessed by the Investigator. * Participants must have ECOG performance status ≤1. Main Exclusion Criteria: * Participants must not have received more than one line of prior systemic treatment for advanced/metastatic NSCLC. * Participants must not have a prior malignancy requiring treatment. * Participants must not have a known or detected clinically active central nervous system (CNS) involvement by NSCLC or other tumors, e.g., with symptomatic metastases and/or carcinomatous meningitis * Participants must not have any active autoimmune disease that has required systemic treatment in past 3 months before planned treatment start (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). * Participants must not have interstitial lung disease or a history of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Visugromab RDE (recommended dose for expansion) · Nivolumab · Docetaxel

  • Group 2 · Studied intervention

    Visugromab 6mg/kg · Nivolumab · Docetaxel

  • Group 3 · Studied intervention

    Visugromab RDE (recommended dose for expansion) · Nivolumab

  • Group 4 · Active treatment comparison

    Placebo Saline Infusion · Docetaxel

Start of the whole study
7 October 2025
Completion of the whole study
1 October 2031 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Updated in the registry: 26 October 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07407933Phase 1Listed as recruiting

Advanced solid tumours: YL201 alongside other cancer treatments

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Craiova

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07407933. This contact may be in another country; ask which language you can use.

MediLink Study Team

86 0512-62858368 (dialling format unconfirmed)

clinicaltrials@medilinkthera.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Craiova

Who can take part

Advanced solid tumours: YL201 alongside other cancer treatments

This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety and tolerability of YL201 in combination with fixed dose of atezolizumab. The planned dose levels of YL201 are 1.2 mg/kg, 1.6 mg/kg and 2.0 mg/kg. Part 2 consists of a dose optimization stage followed by a dose expansion stage. During the dose optimization stage, participants will be randomized 1:1:1 to receive either YL201 at 1.2 mg/kg,1.6 mg/kg or 2.0 mg/kg Q3W in combination with fixed dose of atezolizumab. The decision to initiate the dose expansion stage in Part 2 and choose one or two of the YL201 dose level(s) will be based on the review of safety, PK, and efficacy from the dose optimization stage. Treatment will continue until disease progression, unacceptable toxicity, or withdraw of consent.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1.18 years of age or older. 2. Histologically or cytologically confirmed diagnosis of ES-SCLC 3. Eastern Cooperative Oncology Group performance status of 0 or 1 4. Adequate hematologic and end-organ function Exclusion Criteria: 1. No prior systemic anti-cancer treatment for ES-SCLC 2. No prior treatment targeting B7H3 or topoisomerase I inhibitor 3. No clinically active brain metastases or spinal cord compression 4. No current or history of interstitial lung disease (ILD)/ pneumonitis 5. No clinically significant cardiovascular disease (eg, New York Heart Association class II to IV congestive heart failure) Other protocol-defined inclusion/ exclusion criteria may apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    YL201 · Atezolizumab

  • Group 2 · Studied intervention

    YL201 · Atezolizumab

  • Group 3 · Studied intervention

    YL201 · Atezolizumab

Start of the whole study
31 March 2026
Completion of the whole study
February 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Updated in the registry: 17 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06203210Phase 3Listed as recruiting

Relapsed small cell lung cancer: ifinatamab deruxtecan compared with the doctor's choice of treatment

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Minimum age: 18 years

Centres in: București · Craiova

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06203210. This contact may be in another country; ask which language you can use.

Daiichi Sankyo Contact for Clinical Trial Information

9089926400 (dialling format unconfirmed)

CTRinfo@dsi.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Craiova

Who can take part

Relapsed small cell lung cancer: ifinatamab deruxtecan compared with the doctor's choice of treatment

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria Participants must meet all the following criteria to be eligible for randomization into the study: 1. Sign and date the informed consent form (ICF) prior to the start of any study-specific qualification procedures. 2. Adults greater than or equal to (≥)18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed. 3. Has histologically or cytologically documented extensive-stage small cell lung cancer (ES-SCLC). 4. The participant must provide adequate baseline tumor samples with sufficient quantity and quality of tumor tissue content. 5. Has received prior therapy with only one prior platinum-based line as systemic therapy for SCLC with at least 2 cycles of therapy and a chemotherapy free-interval \[CTFI\] (duration from stop date of the platinum agent in 1L therapy to radiological PD) of ≥30 days. 6. Has at least 1 measurable lesion according to RECIST v1.1 as assessed by the investigator. 7. Has documentation of radiological disease progression on or after the most recent systemic therapy. 8. Has ECOG PS of less than or equal to (≤)1 within 7 days prior to Cycle 1 Day 1 (C1D1). 9. Participants with brain metastasis/leptomeningeal disease are eligible if protocol specified criteria are met. Exclusion Criteria Participants who meet any of the following criteria will be disqualified from entering the study: 1. Has received prior treatment with orlotamab, enoblituzumab, or other B7 homologue 3 (B7-H3) targeted agents, including I-DXd. 2. Prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities. 3. Has received any of the comparators used in this study or any topoisomerase I inhibitor. 4. Has inadequate washout period before randomization as specified in the protocol. 5. Has any of the following conditions within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event. 6. Has uncontrolled or significant cardiovascular (CV) disease. 7. Has clinically significant corneal disease. 8. All of the following indicators of interstitial lung disease (ILD)/pneumonitis are excluded: 1. Any history of ILD/pneumonitis irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids. 2. Current diagnosis of ILD. 3. Clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out. Radiographic findings may include presence of lung parenchymal fibrosis, combined fibrosis and emphysema (CPFE), and/or interstitial lung abnormalities such as reticular opacities, traction bronchiectasis, honeycombing, or extensive ground glass opacities. Screening computed tomography (CT) scans must be submitted for independent central radiology review and results before randomization. 9. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses, including, but not limited to, any underlying pulmonary disorder and potential pulmonary involvement caused by any autoimmune, connective tissue, or inflammatory disorders, prior pneumonectomy, or requirement for supplemental oxygen.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Ifinatamab deruxtecan

  • Group 2 · Active treatment comparison

    Topotecan · Amrubicin · Lurbinectedin

Start of the whole study
21 May 2024
Completion of the whole study
1 December 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Updated in the registry: 6 August 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06908304Phase 3Listed as recruiting

Advanced lung cancer, third line: THIO with cemiplimab compared with chemotherapy

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

Minimum age: 18 years

Centres in: Craiova · Timișoara

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06908304. This contact may be in another country; ask which language you can use.

Matthew Failor

704-936-8435 (dialling format unconfirmed)

mfailor@maiabiotech.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Craiova

Timișoara

Who can take part

Advanced lung cancer, third line: THIO with cemiplimab compared with chemotherapy

THIO is a first-in-class small molecule telomere targeting agent, in development for the treatment of non-small cell lung cancer (NSCLC) in combination with cemiplimab (LIBTAYO®). THIO is preferentially incorporated into telomeres sequence in telomerase-positive cells leading to rapid telomere uncapping, genomic instability, and cell death. Cemiplimab is a programmed cell death protein 1 (PD-1) inhibitor recently approved as a first-line treatment for patients with locally advanced or metastatic NSCLC with 50% or more PD-L1 expression. It is hypothesized that THIO administration prior to cemiplimab would restore tumor responses to immunotherapy in subjects who either developed resistance or relapsed after receiving first line treatment with an immune check point inhibitor.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: 1. At least 18 years of age at the time of signing the Informed Consent Form (ICF) prior to initiation of any study specific activities/procedures. Disease Characteristics 2. Stage 3b or 4 histologically or cytologically confirmed NSCLC. Note: Stage is determined at the time of diagnosis. 3. Two (2) prior lines of systemic treatment for advanced/metastatic disease, including an ICI (anti-PD-1/PD-L1) and a platinum-based chemotherapy (given in combination or in separate lines) for advanced/metastatic disease. Note: The combination of primary therapy followed by maintenance is considered as one line of therapy. Prior treatment with docetaxel is preferred (but not mandated) and is a pre-specified stratification factor. 4. Documented progression or intolerance following the most recent line of therapy. * Stage 4 subjects - must have progressed or relapsed after first-line treatment. * Stage 3b subjects - must have already failed, or be ineligible for, local, curative-intent therapy including surgery, and/or chemoradiation. Note: Local, curative-intent therapy including surgery, and/or chemoradiation is not considered a treatment line in the advanced setting. 5. Documented secondary resistance to the prior ICI treatment, as defined by the SITC IRTF (Kluger, 2020): Resistance phenotype Drug exposure requirements Best response Confirmation scan for PD requirement Confirmation scan timeframe Secondary resistance ≥ 6 months CR, PR, SD for \> 6 months Yes \[1\] At least 4 weeks after disease progression (per RECIST V1.1) \[1\] Other than when tumor growth is very rapid, and subjects are deteriorating clinically. Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease 6. No prior targeted therapy for driver mutations. 7. At least one measurable target lesion that meets the definition of RECIST v1.1, with documented progression following the most recent line of therapy. 8. An archival tissue sample (formalin fixed paraffin-embedded \[FFPE\] tissue block or unstained slides) is required if tissue is available at baseline. Note: The sample does not need to be received by the central laboratory prior to Cycle 1, Day 1 (C1D1). Subjects without archival tissue available at baseline may be eligible with Medical Monitor approval. Diagnostic Assessments 9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 10. Demonstrate adequate organ function as defined below. All screening laboratories should be performed up to 14 days before initiating IP: Bone marrow function: ○ Neutrophil count ≥ 1500/mm3, hemoglobin ≥ 9.0 g/dL, platelet count ≥ 100,000/mm3 Liver function: * Total bilirubin ≤ 1.5 x the upper limit of normal (ULN), up to ≤ 3 × ULN if due to Gilbert's syndrome * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × ULN. Note: For subjects with liver metastases present at baseline, ALT and/or AST ≤ 3 × ULN is permitted. Renal function: ○ Creatinine clearance (CrCl) ≥ 60 mL/min calculated by the Cockcroft-Gault formula using actual body weight (see Table 18) or 24-hour urine collection. Gender and Reproductive Requirements 11. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin \[HCG\]) within 72 hours prior to receiving the first administration of IP. 12. Contraception use: In the THIO / cemiplimab arm: * WOCBP must agree to use a highly effective birth control and refrain from oocyte donation during the study (prior to the first dose with THIO, for the duration of the treatment with THIO, and for six months after the last dose of study treatment, if conception is possible during this interval). * Unless permanently sterile by bilateral orchidectomy, male subjects and WOCBP partners of male subjects should use a combination of the methods specified for female subjects in Appendix 4, Section 10.4 along with a male condom, from start of study treatment, for the duration of the treatment, and for six months after the last dose of study treatment. Male subjects should also refrain from sperm donation during this time. In the single-agent chemotherapy arm: For WOCBP, male subjects and WOCBP partners of male subjects, contraception requirements should follow the relevant product's package labelling and standard of care. Note: Contraception use by men or women in both treatment arms should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Informed Consent 13. Capable and willing to give signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Exclusion Criteria: 1. For subjects who have received prior treatment with a checkpoint inhibitor: primary resistance to prior checkpoint inhibitor, as defined by the SITC IRTF (Kluger, 2020): Resistance phenotype Drug exposure requirements Best response Confirmation scan for PD requirement Confirmation scan timeframe Primary resistance ≥ 6 weeks PD; SD for \< 6 months Yes \[1\] At least 4 weeks after initial disease progression (per RECIST v1.1) \[1\] Other than when tumor growth is very rapid, and subjects are deteriorating clinically. Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; SD=stable disease Note: Subjects with drug exposure \> 6 weeks who achieved a partial or complete response then progressed before six months, would still be eligible. 2. Untreated or symptomatic central nervous system (CNS) metastases. Note: Subjects with treated asymptomatic brain metastasis are eligible. 3. Prior chemotherapy and/or non-biologic targeted therapy within 28 days, or biologic targeted therapy, immunotherapy, and/or radiation therapy within 42 days prior to start of study treatment. Note: Subjects who receive targeted radiation therapy for localized palliative care may be eligible to start study treatment earlier than 42 days with Medical Monitor agreement. 4. Prior treatment with cemiplimab. 5. Prior treatment with a targeted therapy for an epidermal growth factor receptor (EGFR) mutation. 6. Received blood, red blood cell or platelet transfusion within 14 days prior to start of study treatment. 7. Any live, attenuated, inactivated or research vaccines within 30 days prior to start of study treatment. Note: Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. 8. Prior allogeneic hematopoietic stem cell transplant or solid organ transplant. 9. Undergone major surgery within 28 days prior to start of study treatment. Medical conditions 10. Have not recovered to Grade ≤ 1 from adverse events due to prior anti-cancer treatment. 11. Ongoing immune-related / stimulated adverse events (irAEs) from other agents or required permanent discontinuation of prior ICIs due to irAEs. Note: Subjects with resolved irAE may be allowed to enroll following consultation with the Medical Monitor. 12. Active gastrointestinal bleeding as evidenced by either hematemesis or melena. 13. History of another concurrent malignancy other than the present condition (except nonmelanoma skin cancer or carcinoma in situ of the cervix), unless in complete remission and off all therapy for that disease for a minimum of three years. 14. A condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to start of study treatment. Note: Inhaled or topical steroids, adrenal replacement doses 10 mg daily prednisone equivalents, and systemic corticosteroids to manage adverse events are permitted in the absence of active autoimmune disease. 15. Active, uncontrolled bacterial, viral or fungal infections, requiring systemic therapy within 14 days of screening. 16. Positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active hepatitis B or hepatitis C. 17. Significant cardiovascular impairment (history of New York Heart Association Functional Classification System Class III or IV) or a history of myocardial infarction or unstable angina within the past six months prior to start of study treatment. 18. QT interval corrected for heart rate (using Fridericia's correction formula; QTcF) \> 480 msec at screening (based on average of triplicate electrocardiograms \[ECGs\] at baseline). Note: If the QTc is prolonged in a subject with a pacemaker or bundle branch block, the subject may be enrolled in the study if confirmed by the Medical Monitor. 19. Active autoimmune diseases or history of autoimmune diseases that may relapse, with the following exceptions: * Controlled Type 1 diabetes * Hypothyroidism (provided it is managed with hormone replacement therapy only) * Controlled celiac disease * Skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis, or alopecia) * Any other disease that is not expected to recur in the absence of external triggering factors. 20. Pregnancy or lactating. 21. A serious nonmalignant disease (e.g., psychiatric, substance abuse, uncontrolled intercurrent illness, interstitial lung disease etc.) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. 22. Any other condition that, in the opinion of the Investigator, would prohibit the subject from participating in the study. Prior / concurrent clinical study experience 23. Currently enrolled in a clinical study involving another investigational product or nonapproved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. Other 24. History of allergy to excipients of THIO, cemiplimab or any of the chemotherapies under study.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    6-Thio-2'-Deoxyguanosine · Cemiplimab

  • Group 2 · Active treatment comparison

    Docetaxel · Vinorelbine · Gemcitabine alone

Start of the whole study
8 December 2025
Completion of the whole study
31 December 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Updated in the registry: 12 January 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07195695Phase 3Listed as recruiting

Stage II-IIIB HER2-mutated lung cancer after surgery: zongertinib compared with standard treatment

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Minimum age: 18 years

Centres in: București · Ovidiu

See all centres (3)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07195695. This contact may be in another country; ask which language you can use.

Boehringer Ingelheim

1-800-243-0127 (dialling format unconfirmed)

clintriage.rdg@boehringer-ingelheim.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Ovidiu

Who can take part

Stage II-IIIB HER2-mutated lung cancer after surgery: zongertinib compared with standard treatment

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion criteria: 1. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial 2. Patients must be ≥18 years old or over the legal age of consent in their country 3. Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use dual highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information and in the study protocol 4. HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor receptor 2 (HER2) mutations 5. Histology and tumor sample: Histologically confirmed diagnosis of primary NSCLC 6. An archival tumor tissue sample must be submitted to the central laboratory after inclusion of the patient to retrospectively confirm the HER2 status 7. Staging: Pretherapeutic classification not exceeding Stage IIIB 8. Performance status and organ function: * Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 * Adequate organ function based on laboratory values Further inclusion criteria apply. Exclusion criteria: 1. Diagnosis of NSCLC with mixed histology/positive neuroendocrine markers (synaptophysin/CD56) 2. Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to randomization 3. Treatment with radiation therapy for primary NSCLC 4. Co-occurring actionable mutation with approved targeted therapy (e.g. Epidermal growth factor receptor (EGFR) or Anaplastic lymphoma kinase (ALK)) 5. Any investigational drug within 5 half-lives of the compound or any of its related material, if known 6. History or presence of * Active or known pre-existing or history of non-infectious interstitial lung disease/pneumonitis * Active infectious disease requiring systemic therapy * Uncontrolled gastrointestinal disorders affecting drug intake/absorption * Previous or concomitant malignancies within the last 3 years, except certain effectively treated cancers * Significant and/or uncontrolled cardiovascular abnormalities, QT interval corrected for heart rate by Fridericia formula (QTcF) \>470 msec, or ejection fraction \<50% Further exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    Zongertinib

  • Group 2 · Active treatment comparison

    Pembrolizumab · Atezolizumab · Durvalumab · Nivolumab

Start of the whole study
16 January 2026
Completion of the whole study
2 September 2036 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Updated in the registry: 18 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07325136Phase 1Listed as recruiting

Relapsed or refractory small cell lung cancer: BMS-986525 alone and in combination

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Minimum age: 18 years

Centres in: Craiova · Timișoara

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07325136. This contact may be in another country; ask which language you can use.

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

855-907-3286 (dialling format unconfirmed)

Clinical.Trials@bms.com

First line of the email MUST contain NCT # and Site #.

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Craiova

  • Centrul de Oncologie Sf. Nectarie SRL

    Contact for this study

    Michael Schenker

    Centre code in the registry: 0003

    +40 727 774 974

    Source: study registry

Timișoara

  • Oncohelp Medical Center

    Contact for this study

    Cristina Oprean

    Centre code in the registry: 0023

    +40 745 148 485

    Source: study registry

Who can take part

Relapsed or refractory small cell lung cancer: BMS-986525 alone and in combination

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria * Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC). * Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines. * In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy. Exclusion Criteria * Participants must not have any untreated CNS metastases. * Participants must not have an active, known or suspected autoimmune disease. * Participants must not have had a prior organ or tissue allograft. * Other protocol-defined Inclusion/Exclusion criteria apply.

What taking part involves

Group assignment is not random. The team explains the assignment specified in the protocol.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    BMS-986525

  • Group 2 · Studied intervention

    BMS-986525

  • Group 3 · Studied intervention

    BMS-986525 · Pumitamig

  • Group 4 · Studied intervention

    BMS-986525 · Pumitamig

Start of the whole study
3 February 2026
Completion of the whole study
24 April 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Updated in the registry: 14 September 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07472517Phase 3Listed as recruiting

Advanced small cell lung cancer: obrixtamig added to atezolizumab and chemotherapy, compared with standard chemotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Minimum age: 18 years

Centres in: București · Cluj-Napoca

See all centres (2)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07472517. This contact may be in another country; ask which language you can use.

Boehringer Ingelheim

1-800-243-0127 (dialling format unconfirmed)

clintriage.rdg@boehringer-ingelheim.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Who can take part

Advanced small cell lung cancer: obrixtamig added to atezolizumab and chemotherapy, compared with standard chemotherapy

This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival when compared to standard treatment alone. Obrixtamig is an antibody-like molecule that may help the immune system fight cancer. Another purpose of the study is to test a medical device being developed to measure levels of the tumour marker DLL3. Participants are put into 2 groups randomly, which means by chance. One group receives obrixtamig and standard treatment. The other group receives standard treatment without obrixtamig. All treatments are given as infusions into a vein. Participants are in the study for up to 3 years. During this time, they visit the study site regularly. Participants in the group receiving obrixtamig stay overnight at the study site following the first 2 obrixtamig treatments. At the visits, doctors check the size of the tumour(s). The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria : 1. Patients with histologically confirmed Extensive-stage Small Cell Lung Cancer (ES-SCLC) 2. Patients without any previous systemic anti-cancer treatment for ES-SCLC. Patients who received previous systemic anti-cancer treatment during limited stage are eligible if the treatment has been completed more than 6 months before the diagnosis of ES-SCLC. 3. Adequate archival formalin-fixed paraffin-embedded (FFPE) tumour tissue, as specified in the Laboratory Manual, must be available for central laboratory analysis of Delta-like ligand 3 (DLL3) expression status and other biomarkers. The central laboratory investigational VENTANA DLL3 (SP347) RxDx test result must be available prior to randomisation. 4. Patients with asymptomatic brain metastasis are eligible if they meet one of the following criteria: * Treatment for brain metastases (e.g. whole brain radiation therapy, stereotactic radiotherapy, or radiosurgery) completed at least 7 days prior to randomisation and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 7 days prior to randomisation * Untreated brain metastases that do not require treatment and the patient is neurologically stable without the use of glucocorticoids or therapeutic anti-convulsant for at least 28 days prior to randomisation 5. Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 6. Eligible for continuing carboplatin + etoposide + atezolizumab regimen as first-line Standard of care (SoC) treatment within 28 days after the start of the initial cycle of standard therapy 7. Eligible to receive treatment with full dose of atezolizumab, carboplatin, and etoposide as first-line SoC treatment, in accordance with the approved Summary of Product Characteristics if provided centrally or approved local product label if provided by the trial site Further inclusion criteria apply. Exclusion Criteria : 1. Presence of leptomeningeal disease and/or carcinomatous meningitis 2. Previous treatment targeting DLL3 (e.g. T cell engagers (TcEs), cell therapies, antibody-drug conjugates, or radiopharmaceuticals) 3. Radiotherapy of any anatomical site within 7 days prior to randomisation 4. Toxicity from previous treatments that has not resolved to ≤ Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline. Patients with alopecia, any grade, CTCAE ≤Grade 2, asthenia/fatigue, amenorrhea/menstrual disorders any grade, CTCAE Grade ≤2 peripheral neuropathy, and/or CTCAE Grade 2 endocrinopathies controlled by replacement therapy, and toxicities, which are considered irreversible but stable for at least 4 weeks prior to randomisation, per investigator judgment may be eligible. Note: Patients who developed toxicity from the cycle of standard therapy received prior to randomisation are eligible if adequate organ function is ensured as described 5. Patient with active autoimmune disease or a documented history of autoimmune disease that requires systemic treatment (e.g. glucocorticoids or immunosuppressive drugs). Patients with vitiligo, resolved childhood asthma/atopy, alopecia, or any chronic skin condition that does not require systemic therapy, patients with autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and/or controlled Type 1 diabetes mellitus on a stable insulin regimen may be included if in the opinion of the investigator it is appropriate and safe to do so. Further exclusion criteria apply.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    obrixtamig · atezolizumab · carboplatin · etoposide

  • Group 2 · Studied intervention

    atezolizumab · carboplatin · etoposide

Start of the whole study
13 April 2026
Completion of the whole study
30 July 2029 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

Updated in the registry: 10 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT06303505Phase 1Listed as recruiting

Platinum-resistant ovarian cancer or relapsed lung adenocarcinoma: first-in-human test of TUB-040

The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives of this study are: Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO). Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 . Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.

Minimum age: 18 years

Centres in: Cluj-Napoca

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT06303505. This contact may be in another country; ask which language you can use.

Gilead Clinical Study Information Center

GileadClinicalTrials@gilead.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Cluj-Napoca

Who can take part

Platinum-resistant ovarian cancer or relapsed lung adenocarcinoma: first-in-human test of TUB-040

The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives of this study are: Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO). Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 . Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Key Inclusion Criteria (for all phases) 1. Male or non-pregnant, non-breastfeeding female, age 18 years or older at the date of consent. 2. Disease not amenable to curative intent treatment. 3. Individuals have exhausted the standard of care treatment (SoC) with expected survival benefit and are not denied SoC with expected survival benefit by participating in the trial. 4. Individuals with previous systemic topoisomerase I inhibitor treatment (e.g., Topotecan) are allowed in the study. 5. Radiologically measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the INV. 6. Eastern Cooperative Oncology Group (ECOG) 0-1. 7. Have a life expectancy of more than 12 weeks for disease-related mortality, as evaluated by the INV. 8. Individuals must be willing to sign an archival tissue release form for research purposes and determination of biomarker expression. 9. Individuals must be willing to undergo a non-contrast high resolution computed tomography (HRCT) of the thorax scan and pulmonary function testing (PFT) at screening. 10. Adequate organ function 11. Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤grade 1 (except alopecia, hyperpigmentation, or discoloration (incl. vitiligo) of the skin and nails, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone \[or equivalent\], chronic grade 2 peripheral sensory neuropathy after prior taxane therapy or anticancer treatment such as but not limited to immune oncology therapy (IOs)). 12. Individuals of childbearing potential (FCBP) who are sexually active with a non-sterilized partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of individuals assigned female at birth. 13. In the opinion of the investigator, the individual must be able to understand, give written informed consent, and comply with all study-related procedures, medication use, and evaluations. 14. The individual must not have a history of non-compliance with medical regimens or be considered potentially unreliable and/or uncooperative. 15. The individual must be willing to sign and date the informed consent form (ICF) Key Exclusion Criteria (for all phases) 1. The individual is pregnant, lactating or breastfeeding or has a positive serum pregnancy test during the screening period. 2. History of hypersensitivity to exatecan or excipients of the TUB-040 formulation. 3. Individuals are not allowed to participate in interventional clinical studies either concurrently or within the previous 28 days or within 5 half-lives of any investigational pharmacologic agents or imaging materials, including dyes, investigational surgical techniques, or devices. 4. Individuals with spinal cord compression or active central nervous system disease, and/or carcinomatous meningitis. 5. Prior radiotherapy \<2 weeks from trial inclusion. 6. Major surgery within 21 days prior to signing the ICF, unless the individual is recovered at that time. 7. Has a history of non-infectious interstitial lung disease/pneumonitis (ILD)/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis. 8. Has an oxygen saturation of \<93% on room air at rest. 9. Has a QTcF \>470 ms 10. History of nephrotic syndrome 11. Active corneal disease, or history of corneal disease within 12 months prior to enrollment. 12. Active, uncontrolled or severe impairment of the urogenital, renal, hepatobiliary, cardiovascular, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the investigator, would predispose the individual to the development of complications from the administration of protocol therapy. 13. History of another malignancy with ongoing treatment or not yet free from disease for 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome. 14. Documented other concurrent non-malignant comorbidities such as unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, acute myocarditis, or congestive heart failure (CHF) (New York Heart Association III or IV). 15. Any anti-tumor chemotherapy, systemic anti-cancer therapy, radiotherapy (except for local radiation therapy of lesions that may cause imminent complications), hormonal therapy, immunotherapy, or corticoid therapy. 16. Concurrent use of strong inhibitors or strong inducers of CYP3A4 17. Live vaccines within 30 days prior to study entry. 18. Individuals with acute or chronic infections such as: 1. Individuals who are HBsAg positive are eligible if they have received Hepatitis B virus (HBV) anti-viral therapy for at least 4 weeks and have an undetectable HBV viral load prior to randomization. 2. Individuals with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. 3. HIV infected individuals must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease 4. Any other known unresolved and active bacterial, viral, fungal, mycobacterial, or other infection at screening. 5. History of severe and recurrent infections per INV judgment. 6. History of progressive multifocal leukoencephalopathy Note: Other protocol defined Inclusion/Exclusion criteria may apply.

What taking part involves

Group assignment is not random. The team explains the assignment specified in the protocol.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Studied intervention

    TUB-040

  • Group 2 · Studied intervention

    TUB-040

  • Group 3 · Studied intervention

    TUB-040 · Bevacizumab

  • Group 4 · Studied intervention

    TUB-040

  • Group 5 · Studied intervention

    TUB-040

Start of the whole study
12 June 2024
Completion of the whole study
December 2027 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Updated in the registry: 3 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

NCT07365319Phase 2Listed as recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Minimum age: 18 years

Centres in: Cluj-Napoca

See all centres (1)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07365319. This contact may be in another country; ask which language you can use.

Elelta Shiferraw

314-209-3659 (dialling format unconfirmed)

shiferrawe@eikontx.com

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

Cluj-Napoca

Who can take part

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Key Inclusion Criteria: 1. Participant must be ≥ 18 years old at the time of signing the informed consent. 2. Participant has a life expectancy of at least 3 months. 3. Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC. 4. Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country. 5. Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions. 6. Participant has not received prior systemic therapy for advanced/metastatic NSCLC. Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and/or radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible. 7. Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment. 8. Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is \< 3yrs old). Key Exclusion Criteria: 1. has small cell elements present histologically and/or the tumors are not predominantly non-squamous or squamous NSCLC. 2. is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo. 3. has had major surgery (\< 3 weeks prior to the first dose of study intervention administration). 4. has received a live-virus vaccination within 30 days of the start of study intervention initiation. 5. has received radiation therapy within 7 days of the first dose of study intervention administration. 6. has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.

What taking part involves

Participants are randomly assigned to the study groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Placebo comparison

    Pembrolizumab (KEYTRUDA®) · Placebo · Paclitaxel + Carboplatin · Nab-paclitaxel + Carboplatin · Pemetrexed + Cisplatin /Carboplatin

  • Group 2 · Studied intervention

    EIK1001 · Pembrolizumab (KEYTRUDA®) · Paclitaxel + Carboplatin · Nab-paclitaxel + Carboplatin · Pemetrexed + Cisplatin /Carboplatin

  • Group 3 · Studied intervention

    EIK1001 · Pembrolizumab (KEYTRUDA®) · Paclitaxel + Carboplatin · Nab-paclitaxel + Carboplatin · Pemetrexed + Cisplatin /Carboplatin

Start of the whole study
15 June 2026
Completion of the whole study
31 December 2040 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Full title

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Updated in the registry: 16 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Observational studies · one study

You do NOT receive a new treatment here. You have your usual care, and researchers collect information about how it goes. Useful for people after you, but it does not change your own care.

NCT07284121Listed as recruiting

Observational study: how atezolizumab treatment goes in routine practice, as patients report it

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Minimum age: 18 years

Centres in: București · Cluj-Napoca · Galați · and 4 more cities

See all centres (9)

These centres appear in the record of a recruiting study. Confirm availability with the team before travelling. One centre may have several teams with different contacts.

Central study contact

To find the team and exact institution in your chosen city, quote study NCT07284121. This contact may be in another country; ask which language you can use.

Reference Study ID Number: MO45893 https://forpatients.roche.com/ No attachments to email below.

global-roche-genentech-trials@gene.com

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Source: study registry

We could not read the directory's general contacts right now. Contacts published in the registry are shown in this card.

București

Cluj-Napoca

Galați

Iași

Ploiești

Satu Mare

Timișoara

Who can take part

Observational study: how atezolizumab treatment goes in routine practice, as patients report it

This is a non-interventional, multi-country, multi-centre, multicohort, primary data collection study, designed to assess patients' reported satisfaction with Atezolizumab Subcutenous (SC) treatment and Health-related Quality of Life (HRQoL), as well as the effectiveness and safety of Atezolizumab SC in participants treated for selected approved indications in routine clinical practice.

Minimum age:
18 years
Maximum age:
Not specified in the record consulted
Participant sex, as recorded in the registry:
All sexes

This is an overview, not confirmation of eligibility. The study team reviews your records, the inclusion and exclusion criteria and the other protocol requirements.

Criteria published in the registry — English original

Inclusion Criteria: * Participants must have one of the following confirmed diagnoses for which atezolizumab is approved in the local SmPC: * Early stage NSCLC following complete resection and platinum-based chemotherapy with a high risk of recurrence and PD-L1 expression on ≥ 50% of TC and with no EGFR-mutant or ALK-positive NSCLC * Metastatic stage NSCLC with PD-L1 expression on ≥ 50% TC or ≥ 10% tumor infiltrating immune cells (IC) and with no EGFR-mutant or ALK-positive NSCLC not previously treated * Extensive-stage small cell lung cancer (ES-SCLC) not previously treated * Advanced or unresectable HCC not previously treated with systemic therapy * Should not have received \> 4 prior cycles of IV Atezolizumab Exclusion Criteria: * Not receiving treatment with Atezolizumab according to standard of care and in line with the current SmPC or local labelling * Receiving concomitant systemic anticancer therapy at the time of initiation of Atezolizumab or an Atezolizumab-containing regimen for treatment of the same disease, as per label * Receiving treatment with Atezolizumab as part of a clinical trial, pre-approval access program, compassionate use program, expanded use program, post-trial access program, or continued access program * Unwilling to complete questionnaires related to treatment satisfaction and treatment-related quality of life

What taking part involves

The record does not specify how participants are assigned to groups.

These source names are associated with each group and may include alternatives or different stages. They do not imply that all are given simultaneously. The team explains the regimen, doses and schedule.

  • Group 1 · Group described in the registry

    Atezolizumab

  • Group 2 · Group described in the registry

    Atezolizumab

  • Group 3 · Group described in the registry

    Atezolizumab

  • Group 4 · Group described in the registry

    Atezolizumab

Start of the whole study
15 July 2025
Completion of the whole study
31 December 2028 (estimated)

These are global study dates, not an individual's participation duration or an enrolment deadline.

Confirm participation duration, visit frequency and possible admissions with the centre team; they cannot be inferred from global study dates.

Ask the study team before travelling:

  • whether places are available at the chosen centre and how the first assessment is arranged
  • how often you need to attend the centre and whether a hospital stay is necessary
  • whether travel or accommodation costs are covered and under what conditions
  • which documents you need to prepare and whether a family member or carer can accompany you
Original registry title

A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice

Updated in the registry: 6 November 2026

Data consulted: 19 November 2026

See the official record ↗

If the official record does not open, you can still read the information and contacts in this card. The ClinicalTrials.gov record is in English.

Source: ClinicalTrials.gov, the public registry of the US National Library of Medicine. Data retrieved on 19 Nov 2026.

Worth reading before you talk to your doctor

Material from our library to help you prepare your questions.

Where the official information lives

View the records in the official registries.

Where the data on this page comes from

The counts come from ClinicalTrials.gov and reflect trials marked in the registry as recruiting that also have at least one site in Romania marked as recruiting. We show cities, centre names and contacts when published. General contacts added from the OncoDots directory are labelled separately. A “recruiting” status does not guarantee that a site is still accepting patients on the day you check, because the registry may lag behind the situation at the hospital. For any decision, consult the official record and discuss it with your doctor.